document incorporate reference part ii iii portion registrant annual report shareholder fiscal year annual reportpart iii portion registrant proxy statement annual meeting shareholder file day close registrant fiscal year proxy statementitem pag e business general segment business geographic area raw material patent trademark seasonality competition research development environment regulation available information risk factor b unresolved staff comment property legal proceeding submission matter vote security holder executive officer registrant ii market registrant common equity relate stockholder matter issuer purchase equity security select financial datum management discussion analysis financial condition result operation quantitative qualitative disclosure market risk financial statement supplementary data change disagreement accountant account financial disclosure control procedure b information iii director executive officer corporate governance executive compensation security ownership certain beneficial owner management relate stockholder matter certain relationship relate transaction director independence principal accounting fee service iv exhibit financial statement schedule schedule ii valuation qualifying account signature report independent register public accounting firm financial statement schedule exhibit index exr summary compensation arrangement name executive officer director ex statement computation ratio earning fix charge ex page company annual report shareholder ex subsidiary ex consent pricewaterhousecooper llp exa certification exb certification exa certification exb certification ex cautionary statementtable content item business general johnson johnson subsidiary approximately employee worldwide engage research development manufacture sale broad range product health care field johnson johnson hold company operate company conduct business virtually country world johnson johnsons primary focus product relate human health wellbee johnson johnson incorporate state new jersey companys structure base principle decentralize management executive committee johnson johnson principal management group responsible operation allocation resource company committee oversee coordinate activitie consumer pharmaceutical medical device diagnostic business segment subsidiary business segment exception manage citizen country locate segment business johnson johnsons operating company organize business segment consumer pharmaceutical medical device diagnostic additional information require item incorporate reference narrative tabular graphic description segment operate result caption management discussion analysis result operation financial condition page note segment business geographic area note consolidated financial statement annual report file exhibit report consumer consumer segment include broad range product baby care skin care oral care wound care womens health care field nutritional overthecounter pharmaceutical product major brand include aveeno skin care product bandaid brand adhesive bandage carefree pantiliner clean clear teen skin care product johnson baby adult line product listerine oral care product motrin ib ibuprofen product neutrogena skin hair care product roc skin care product pepcid ac acid controller johnson johnson merck consumer pharmaceutical co rembrandt brand oral care product splenda calorie sweetener stayfree sanitary protection product sudafe cold flu allergy product broad family tylenol acetaminophen product vendme skin care product line product market principally general public sell wholesaler directly independent chain retail outlet world pharmaceutical pharmaceutical segment include product follow therapeutic area antiinfective antipsychotic cardiovascular contraceptive dermatology gastrointestinal hematology immunology neurology oncology pain management urology virology product distribute directly retailer wholesaler health care professional prescription use general public key product pharmaceutical segment include risperdal oral risperidone medication treat symptom schizophrenia bipolar mania irritability associate autistic behavior indicate patient risperdal consta risperidone longacte injectable invegatm paliperdone extend release tablet treatment schizophrenia remicade infliximab biologic approve treatment crohns disease ankylose spondylitis psoriasis psoriatic arthritis ulcerative colitis use treatment rheumatoid arthritis procrit epoetin alfa sell outside eprex biotechnologyderive product stimulate red blood cell production topamax topiramate approve adjunctive monotherapy use epilepsy prophylactic treatment migrane levaquin levofloxacin floxin ofloxacin antiinfective field aciphexpariet proton pump inhibitor comarketed eisai inc duragesicfentanyl transdermal fentanyl transdermal system sell outside durogesic treatment chronic pain offer novel delivery system concerta methylphenidate hcl product treatment attention deficit hyperactivity disorder ortho evratable content norelgestrominethinyl estradiol transdermal system contraceptive patch approve food drug administration fda medical device diagnostic medical device diagnostic segment include broad range product distribute wholesaler hospital retailer principally professional field physician nurse therapist hospital diagnostic laboratory clinic product include cordis circulatory disease management product depuy orthopaedic joint reconstruction spinal care product ethicon wound care women health product ethicon endosurgerys minimally invasive surgical product lifescan blood glucose monitor insulin delivery product orthoclinical diagnostic professional diagnostic product vision care disposable contact lense distribution health care professional market directly surgical supply dealer geographic area international business johnson johnson conduct subsidiary locate country outside united states sell product virtually country world product sell international business include describe segment business consumer pharmaceutical medical device diagnostic principal market product method distribution international business vary country culture product sell international business include develop united states develop subsidiary abroad investment activity country outside united states subject high risk comparable activity investment commercial climate influence restrictive economic policy political uncertainty raw material raw material essential johnson johnsons operate company business generally readily available multiple source patent trademark johnson johnson operating company practice obtain patent protection product process possible licensed number patent relate product manufacturing process aggregate believe material importance johnson johnson operation business sale company large product risperdal remicade account approximately johnson johnsons total revenue respectively fiscal accordingly patent relate product believe material johnson johnson duragesicfentanyl transdermal fentanyl transdermal system lose basic patent protection subject generic competition united states certain international market basic patent cover eprex epoetin alfa expire increase biosimilar competition international market expect duragesicfentanyl transdermal sale decline billion compare impact generic competition combine sale duragesicfentanyl transdermal eprex account approximately johnson johnsons worldwide sale material patent expire expire relate risperdal expire united states december topamax schedule expire united states september company receive pediatric extension risperdal oral fda grant market exclusivity united states june company target file pediatric extension topamax obtain fda grant market exclusivity united states march table content johnson johnsons operating company practice sell product trademark obtain protection trademark available mean trademark protect registration united states country product market johnson johnson consider trademark aggregate material importance operation business seasonality worldwide sale reflect significant degree seasonality spend heavy fourth quarter year quarter reflect increase spending decision principally advertise research development activity competition product line johnson johnsons operating company compete company large small locate world competition strong product line regard number size compete company involve competition research involve development improvement new exist product process particularly significant development new improve product important johnson johnson success area business include protect company portfolio intellectual property competitive environment require substantial investment continue research multiple sale force addition development maintenance customer acceptance product johnson johnsons consumer business involve significant expenditure advertising promotion research development research activity represent significant johnson johnson subsidiary business major research facility locate united states australia belgium brazil canada china france germany india japan netherlands singapore united kingdom cost worldwide companysponsore research activity relate development new product improvement exist product technical support product compliance governmental regulation protection consumer patient exclude inprocess research development charge amount million million million fiscal year respectively cost charge directly income year incur environment johnson johnsons operate company subject variety federal state local environmental protection measure johnson johnson believe operation comply material respect applicable environmental law regulation johnson johnson compliance requirement past year expect material effect capital expenditure cash flow earning competitive position regulation johnson johnson business subject vary degree governmental regulation country operation conduct general trend increasingly stringent regulation united states drug device diagnostic cosmetic industry long subject regulation federal state agency primarily product safety efficacy manufacturing advertising labeling safety report exercise broad regulatory power fda continue result increase amount test documentation require fda clearance new drug device correspond increase expense product introduction similar trend evident major market outside united states cost human health care continue subject study investigation regulation governmental agency legislative body world united states attention focus drug price profit program encourage doctor write prescription particular drug recommend use purchase particular medical device payer potent force market table content place increase attention pay drug medical device price appropriate drug medical device utilization quality cost health care united states implementation medicare prescription drug improvement modernization act deficit reduction act cause uncertainty reimbursement level certain product segment regulatory agency purview johnson johnsons operate company operate administrative power subject company action product withdrawal recall seizure product civil criminal sanction case johnson johnson operating company deem advisable initiate product recall addition business practice health care industry come increase scrutiny particularly united states government agency state attorney general result investigation prosecution carry risk significant civil criminal penalty available information company main corporate web site address wwwjnjcom copy johnson johnsons quarterly report form q annual report current report form k file furnish securities exchange commission sec amendment foregoing provide charge shareholder submit write request secretary principal executive office company call company sec filing available company web site wwwinvestorjnjcomgovernancecfm soon reasonably practicable electronically file furnish sec sec filing available sec web site wwwsecgov addition write charter audit committee compensation benefit committee nominate corporate governance committee board director company principle corporate governance policy business conduct employee code business conduct ethic member board director executive officer available wwwinvestorjnjcomgovernancecfm web site address provide charge shareholder submit write request provide item risk factor applicable item b unresolved staff comment applicable item property johnson johnson subsidiary operate manufacturing facility occupy approximately million square foot floor space manufacturing facility industry segment johnson johnsons business approximately follow square foot segment thousand consumer pharmaceutical medical device diagnostic worldwide total united states facility consumer segment pharmaceutical segment medical device diagnostic segment johnson johnsons manufacturing operation outside united states conduct facility serve business segment table content location manufacture facility major geographic area world follow square foot number geographic area facility thousands united states europe western hemisphere exclude africa asia pacific worldwide total addition manufacture facility discuss johnson johnson subsidiary maintain numerous office warehouse facility world research facility discuss item business research development johnson johnson subsidiary generally seek manufacture facility principally location abroad lease office warehouse facility lease johnson johnson property maintain good operating condition repair utilize information lease obligation note rental expense lease commitment note consolidated financial statement annual report file exhibit report segment information addition property plant equipment contain note segment business geographic area note consolidated financial statement annual report file exhibit report item legal proceeding information set forth note legal proceeding note consolidated financial statement page annual report incorporate reference file exhibit report company subsidiary party number proceeding bring comprehensive environmental response compensation liability act commonly know superfund comparable state law primary relief seek cost past future remediation feasible predict determine outcome proceeding opinion company proceeding material adverse effect result operation cash flow financial position company item submission matter vote security holder applicable executive officer registrant list executive officer johnson johnson february indicate employee company affiliate hold position indicate past year family relationship executive officer arrangement understand executive officer person pursuant executive officer select annual meeting board director executive officer elect board hold office year respective successor elect qualified early resignation removal table content information regard director company include follow executive officer director incorporate reference material caption election director proxy statement age position dominic j caruso member executive committee vice president finance chief financial officera donald casey jr member executive committee worldwide chairman comprehensive care groupb russell c deyo member executive committee vice president general counsel c kaye fostercheek member executive committee vice president human resourcesd colleen goggin member executive committee worldwide chairman consumer groupe sherilyn mccoy member executive committee worldwide chairman surgical care groupf christine poon vice chairman board directors member executive committee worldwide chairman pharmaceuticals group joseph c scodari member executive committeeg nicholas j valeriani member executive committee vice president strategy growthh william c weldon chairman board directors chairman executive committee chief executive officer mr j caruso join company company acquire centocor inc time acquisition senior vice president finance centocor mr caruso name vice president finance ortho mcneil pharmaceutical inc vice president group finance company medical device diagnostic group mr caruso name vice president company group finance organization mr caruso member executive committee vice president finance chief financial officer january b mr casey jr join company hold position president johnson johnson merck consumer pharmaceutical co name president personal product company division johnson johnson consumer companies inc mr casey group president johnson johnson vision care inc name company group chairman vision care november name company group chairman lifescan franchise january member executive committee worldwide chairman comprehensive care group c mr r c deyo join company associate general counsel member executive committee vice president administration vice president general counsel ms k fostercheek join company vice president human resources johnson johnson consumer product company march name vice president human resource consumer personal care group name member human resource leadership team consumer personal care group operating committee ms fostercheek member executive committee vice president human resource company prior join company ms fostercheek serve human resource management position pfizer inc year recently support pharmaceutical business japan asia africa middle east latin america e ms c goggins join company hold position president personal product company name president johnson johnson consumer companies inc company group chairman north america johnson johnson consumer product ms goggin member executive committee worldwide chairman consumer personal care group know consumer group table content f ms mccoy join company associate scientist research development personal product company name vice president research development personal product worldwide division mcneilppc inc vice president marketing skin care franchise ms mccoy global president baby wound care franchise name company group chairman worldwide franchise chairman ethicon inc january member executive committee worldwide chairman surgical care group g mr j c scodari join company president centocor inc company acquire centocor time acquisition president chief operating officer centocor member centocors board director december name company group chairman north american pharmaceutical business member pharmaceutical group operating committee mr scodari name company group chairman biopharmaceutical business mr scodari member executive committee worldwide chairman pharmaceuticals group mr scodari plan retire company march h mr n j valeriani join company hold position president ethicon endosurgery inc name company group chairman ethicon endosurgery additional responsibility johnson johnson medical product medical device diagnostic business canada worldwide franchise chairman depuy franchise mr valeriani member executive committee vice president human resource assume additional responsibility worldwide chairman diagnostic mr valeriani appoint worldwide chairman cardiovascular device diagnostic relinquish human resource responsibility worldwide chairman medical device diagnostic group january mr valeriani vice president strategy growth ii item market registrant common equity relate stockholder matter issuer purchase equity security february record holder common stock company additional information call item incorporate reference material caption management discussion analysis result operation financial condition liquidity capital resource share repurchase dividend information common stock market price note common stock stock option plan stock compensation agreement note consolidated financial statement page shareholder return performance graph annual report file exhibit report item security ownership certain beneficial owner management relate stockholder matter equity compensation plan information report issuer purchase equity securities july company announce board director approve stock repurchase program authorize company buy billion company common stock share repurchase place open market time time base market condition repurchase program time limit suspend period discontinue time share acquire available general corporate purpose company intend fund share repurchase program combination available cash debt company expect triplea credit rating effect share repurchase program addition common stock purchase open market systematic plan relate company compensation program table content follow table provide information respect common stock purchase company fiscal fourth quarter total number share remain purchase maximum number share total number avg price publicly announce purchase share pay plan plan period purchase share program programs october october october november november december total fiscal fourth quarter company repurchase aggregate share company common stock pursuant repurchase program publicly announce july aggregate share openmarket transaction outside program december base closing price company common stock new york stock exchange december share item select financial datum information call item incorporate reference material caption summary operation statistical datum annual report file exhibit report item management discussion analysis financial condition result operation information call item incorporate reference narrative tabular graphic material caption management discussion analysis result operation financial condition page annual report file exhibit report item quantitative qualitative disclosure market risk information call item incorporate reference material caption management discussion analysis result operation financial condition liquidity capital resource finance market risk note summary significant accounting policy financial instrument note consolidated financial statement page annual report file exhibit report item financial statement supplementary datum information call item incorporate reference audit consolidated financial statement note thereto material caption report independent register public accounting firm page annual report file exhibit report table content item change disagreement accountant account financial disclosure applicable item control procedure disclosure control procedure end period cover report company evaluate effectiveness design operation disclosure control procedure company disclosure control procedure design ensure information require disclose company report file submit exchange act record process summarize report time period specify sec rule form disclosure control procedure include limitation control procedure design ensure information require disclose company report file submit exchange act accumulate communicate company management include principal executive principal financial officer person perform similar function appropriate allow timely decision require disclosure william c weldon chairman chief executive officer dominic j caruso chief financial officer review participate evaluation base evaluation messr weldon caruso conclude end period cover report company disclosure control procedure effective management annual report internal control financial reporting section sarbanesoxley act management require assess effectiveness company internal control financial reporting end fiscal year report base assessment company internal control financial report effective management company responsible establish maintain adequate internal control financial reporting company internal control financial reporting design provide reasonable assurance reliability company financial reporting preparation financial statement accordance generally accept accounting principle internal control financial reporting matter design inherent limitation internal control financial reporting determine effective provide reasonable assurance respect financial statement preparation prevent detect misstatement projection evaluation effectiveness future period subject risk control inadequate change condition degree compliance policy procedure deteriorate company management assess effectiveness company internal control financial reporting december make assessment company criterion establish committee sponsor organization treadway commission coso internal controlintegrate framework criterion area control environment risk assessment control activity information communication monitoring company assessment include extensive documenting evaluating testing design operating effectiveness internal control financial reporting base company process assessment describe management conclude december company internal control financial report effective effectiveness company internal control financial reporting december audit pricewaterhousecooper llp independent register public accounting firm state report appear report independent register public accounting firm annual report incorporate reference file exhibit report change internal control financial reporting fiscal quarter end december change companys internal control financial reporting identify connection evaluation refer item materially affect reasonably likely materially affect company internal control financial reporting item b information applicable table content iii item director executive officer corporate governance information call item incorporate reference material caption election director stock ownership section compliance section b beneficial ownership report compliance discussion audit committee caption corporate governance board committee proxy statement material caption executive officer registrant report company policy business conduct cover employee include chief executive officer chief financial officer controller meet requirement sec rules promulgate section sarbanesoxley act policy business conduct available company web site wwwinvestorjnjcomgovernancepoliciescfm copy available shareholder charge write request secretary company principal executive office substantive amendment policy business conduct waiver policy grant chief executive officer chief financial officer controller post company web site wwwinvestorjnjcomgovernancecfm business day retain web site year addition company adopt code business conduct ethic member board director executive officer code business conduct ethic member board director executive officer available company web site wwwinvestorjnjcomgovernancepoliciescfm copy available shareholder charge write request secretary company principal executive office substantive amendment code waiver code grant member board director executive officer post company web site wwwinvestorjnjcomgovernance business day retain web site year item executive compensation information call item incorporate reference material caption compensation discussion analysis executive director compensation compensation committee report proxy statement material incorporate reference material caption compensation committee report proxy statement shall deem furnish file report shall deem incorporate reference filing security act amend securities exchange act amend result furnish extent registrant specifically incorporate reference item security ownership certain beneficial owner management relate stockholder matter additional information call item incorporate reference material caption stock ownership section compliance proxy statement note common stock stock option plan stock compensation agreement note consolidated financial statement page annual report file exhibit report equity compensation plan information follow table provide certain information december concern share company common stock issue exist equity compensation plan table content number security weight average number security issue exercise exercise price remain available outstanding option outstanding warrant future issuance plan category warrant right option right equity compensation plan equity compensation plan approve security holder equity compensation plan approve security holder total include category follow equity compensation plan approve company shareholder stock option plan stock option plan stock compensation plan longterm incentive plan include category share common stock company issuable equity compensation plan assume company acquisition follow company alza corporation scios inc innovasive devices inc inverness medical technology inc centocor inc share list issuable category issue plan approve shareholder company prior acquisition assumption plan company time acquisition option acquire equity acquire company replace option acquire common stock company stock option equity award type plan assumption plan company stock option equity award type plan future share include column issue plan approve shareholder applicable acquire company share issuable scio nonofficer stock option plan share issuable alza nonstatutory plan share issuable warrant inverness medical plan include category share common stock company issuable exercise outstanding stock option companys stock option plan nonemployee director column exclude share reflect column number security issue exercise outstanding option warrant right item certain relationship relate transaction director independence information call item incorporate reference material caption transaction relate person corporate governance director independence proxy statement item principal accounting fee service information call item incorporate reference material caption ratification appointment independent register public accounting firm proxy statement table content iv item exhibit financial statement schedule follow document file report financial statement follow audit consolidated financial statement note thereto material caption report independent register public accounting firm page annual report incorporate reference file exhibit report consolidated balance sheet end fiscal year consolidated statement earning fiscal year consolidated statement equity fiscal year consolidated statement cash flow fiscal year note consolidated financial statement report independent register public accounting firm financial statement schedule schedule ii valuation qualifying account schedule list omit require applicable exhibit require file item l regulation sk information call item incorporate reference exhibit index report table content johnson johnson subsidiaries schedule ii valuation qualifying account fiscal year end december december january dollar millions balance balance beginning end period accrual payment period accrue rebate accrue return accrue promotions subtotal reserve doubtful account reserve cash discount total accrue rebate accrue return accrue promotions subtotal reserve doubtful account reserve cash discount total accrue rebate accrue return accrue promotions subtotal reserve doubtful account reserve cash discount total include reserve customer rebate million million million december december january respectively include million relate previously estimate performancebase rebate allowance manage care contract table content signature pursuant requirement section securities exchange act registrant duly cause report sign behalf undersigned thereunto duly authorize date february johnson johnson registrant w c weldon w c weldon chairman board directors chief executive officer pursuant requirement securities exchange act report sign follow person behalf registrant capacity date indicate signature title date w c weldon chairman board directors february w c weldon chief executive officer director principal executive officer c poon vice chairman board directors director february c poon j caruso chief financial officer principal financial officer february j caruso j cosgrove controller principal accounting officer february j cosgrove coleman director february coleman j g cullen director february j g cullen e johns director february e johns table content signature title date g langbo director february g langbo l lindquist director february l lindquist l f mullin director february l f mullin w perez director february w perez c prince director february c prince reinemund director february reinemund satcher director february satcher table content report independent register public accounting firm financial statement schedule shareholder board directors johnson johnson audits consolidated financial statement effectiveness internal control financial reporting refer report date february appear annual report shareholder johnson johnson report consolidated financial statement incorporate reference annual report include audit financial statement schedule list item opinion financial statement schedule present fairly material respect information set forth read conjunction relate consolidated financial statement pricewaterhousecooper llp pricewaterhousecooper llp new york new york february table content exhibit index reg sk exhibit table description item exhibit ai restate certificate incorporation date april incorporate reference exhibit registrant annual report year end december aii certificate amendment restate certificate incorporation company date incorporate reference exhibit registrant annual report year end january aiii certificate amendment restate certificate incorporation company date incorporate reference exhibit aiii registrant annual report year end december aiv certificate amendment restate certificate incorporation company effective incorporate reference exhibit registrant form q quarterly report quarter end july av certificate amendment restate certificate incorporation company effective april incorporate reference exhibit registrant form q quarterly report quarter end april b bylaw company amend effective january incorporate reference exhibit registrant form k current report file january request security exchange commission registrant furnish copy instrument define right holder long term debt registrant stock option plan nonemployee director incorporate reference exhibit registrant annual report year end december b stock option plan amend incorporate reference exhibit b registrant annual report year end december c stock option plan amend incorporate reference exhibit b registrant annual report year end january stock compensation plan incorporate reference exhibit e registrant annual report year end december e longterm incentive plan incorporate reference exhibit registrant registration statement file commission file f form stock option certificate restrict share nonemployee director certificate longterm incentive plan incorporate reference exhibit registrant form q quarterly report quarter end july g form restrict stock unit certificate longterm incentive plan incorporate reference exhibit registrant form q quarterly report quarter end october h executive bonus plan incorporate reference exhibit registrant form registration statement file commission november file executive incentive plan amend incorporate reference exhibit f registrant annual report year end december j domestic defer compensation certificate extra compensation plan amend incorporate reference exhibit g registrant annual report year end december k defer fee plan nonemployee director amend incorporate reference exhibit h registrant annual report year end january table content reg sk exhibit table description item exhibit l executive income deferral plan amend incorporate reference exhibit registrant annual report year end december excess saving plan incorporate reference exhibit j registrant annual report year end december n supplemental retirement plan incorporate reference exhibit h registrant annual report year end january executive life insurance plan incorporate reference exhibit registrant annual report year end january p stock option gain deferral plan incorporate reference exhibit registrant annual report year end january q estate preservation plan incorporate reference exhibit n registrant annual report year end january r summary compensation arrangement name executive officer director file document statement computation ratio earning fix charge file document page company annual report shareholder fiscal year portion annual report incorporate reference report deem file file document subsidiary file document consent independent register public accounting firm file document certification chief executive officer pursuant section sarbanesoxley act file document b certification chief financial officer pursuant section sarbanesoxley act file document certification chief executive officer pursuant section sarbanesoxley act furnish document b certification chief financial officer pursuant section sarbanesoxley act furnish document cautionary statement pursuant private security litigation reform act safe harbor forwardlooke statement file document management contract compensatory plan copy exhibit list provide charge shareholder submit write request specify desire exhibit secretary principal executive offices company exr yexvwrhtm exr summary compensation arrangement name executive officer director exhibit r summary compensation arrangement name executive officer director compensation arrangement name executive officer follow description compensation arrangement approve compensation benefit committee board directors johnson johnson compensation committee february company chief executive officer chief financial officer highly compensate executive officer name executive officer annual base salary compensation committee approve follow base salary effective february january case mr caruso name executive officer william c weldon chairmanceo dominic j caruso vice president finance cfo christine poon vice chairman russell c deyo vice president general counsel colleen goggin worldwide chairman consumer group performance bonus compensation committee approve follow bonus performance payment performance pay form cash company common stock determined compensation committee mr weldon mr caruso ms poon mr deyo ms goggin stock option restrict share unit grantsthe compensation committee approve follow stock option restrict share unit rsu grant companys longterm incentive plan lti plan stock option grant exercise price fair market value calculate average high low price company common stock new york stock exchange february option exercisable february expire february rsus vest february holder employ company date receive share company common stock rsu mr weldon stock option rsus mr caruso stock option rsus ms poon stock option rsus mr deyo stock option rsus ms goggin stock option rsusnonequity incentive plan awards compensation committee approve follow nonequity incentive plan award recognition performance company certificate extra compensation cec program award pay retirement termination employment end fiscal year cec value unit cec unit value vary time base performance company awards cec unit grant executive officer year mr weldon cec unit mr caruso cec units equity compensation nonemployee directors nonemployee director receive nonretainer equity compensation quarter year lti plan form share restrict common stock fair market value grant date accordingly nonemployee director grant share restrict common stock lti plan february service board restrict share freely transferable february ex yexvhtm ex statement computation ratio earning fix charge exhibit johnson johnson subsidiaries statement computation ratio earning fix charge dollar million fiscal ear end december december january january december determination earning earning provision taxis income fix charge total earning define fix charge rent interest expense capitalization interest total fix charge ratio earning fix charge ratio earning fix charge compute divide sum earning provisio n ta xes income f ix ed charg es fix charge f ixe charg es represent ter est expe ns e int ere st pit alized amortization debt discount appropriate interest factor operating lease ex yexvhtm ex page company annual report shareholder exhibit table content management discussion analysis organization business segment result operation analysis sale business segment analysis consolidate earning provision taxis income liquidity capital resource information cautionary factor affect future result audit consolidated financial statement consolidate balance sheet consolidate statement earning consolidate statement equity consolidate statement cash flow note consolidated financial statement management report internal control financial reporting report independent register public accounting firm summary operation statistical data shareholder return performance graph johnson johnson annual report management discussion analysis result operation financial condition organization business segment description company business segment johnson johnson subsidiaries company approximately employee worldwide engage research development manufacture sale broad range product health care field company conduct business virtually country world primary focus product relate human health wellbee company organize business segment consumer pharmaceutical medical device diagnostic consumer segment include broad range product baby care skin care oral care wound care womens health care field nutritional overthecounter pharmaceutical product product market principally general public sell wholesaler directly independent chain retail outlet world pharmaceutical segment include product follow therapeutic area antiinfective antipsychotic cardiovascular contraceptive dermatology gastrointestinal hematology immunology neurology oncology pain management urology virology product distribute directly retailer wholesaler health care professional prescription use general public medical device diagnostic segment include broad range product principally professional field physician nurse therapist hospital diagnostic laboratory clinic product include cordis circulatory disease management product depuy orthopaedic joint reconstruction spinal care product ethicon wound care women health product ethicon endosurgerys minimally invasive surgical product lifescan blood glucose monitor insulin delivery product orthoclinical diagnostic professional diagnostic product vision care disposable contact lense company structure base principle decentralize management executive committee johnson johnson principal management group responsible operation allocation resource company committee oversee coordinate activitie consumer pharmaceutical medical device diagnostic business segment subsidiary business segment exception manage citizen country locate product line company compete company large small locate world competition strong product line regard number size compete company involve competition research involve development improvement new exist product process particularly significant development new improved product important company success area business include protect company portfolio intellectual property competitive environment require substantial investment continue research multiple sale force addition development maintenance customer acceptance company consumer product involve significant expenditure advertising promotion management objective primary objective company achieve superior level capital efficient profitable growth accomplish company management operate business consistent certain strategic principle prove successful time end company participate growth area human health care commit attain leadership position growth segment development innovative product service new product introduce past year account approximately sale billion sale invest research development increase billion increase reflect management commitment importance ongoing development new differentiate product service sustain longterm growth operating company locate country company view principle decentralize management asset fundamental success broadly base business foster entrepreneurial spirit combine extensive resource large organization ability react quickly local market change challenge company commit develop global business leader drive growth objective business manage long term order sustain leadership position achieve growth provide endure source value shareholder unify management team company dedicated employee achieve objective credo credo provide common set value serve constant reminder company responsibility customer employee communitie shareholder company believe basic principle overall mission improve quality life people enable johnson johnson continue leader health care industry result operation analysis consolidate sale worldwide sale increase billion compare increase sale increase consist follow sale increase volume price currency total sale company billion billion billion represents increase sale international company billion billion billion represents increase johnson johnson annual reportbar chart fiveyear compound annual growth rate worldwide international sale respectively tenyear compound annual growth rate worldwide international sale respectively bar chart international geographic region experience sale growth consist europe western hemisphere exclude asiapacific africa region sale increase include impact currency fluctuation dollar foreign currency positive impact europe western hemisphere exclude asiapacific africa region acquisition pfizer inc consumer healthcare business net relate divestiture increase total sale growth operational growth company customer represent total revenue bar chart analysis sale business segment consumer segment consumer segment sale billion increase change operational growth remain positive currency fluctuation consumer segment sale billion increase international sale billion increase result operation currency fluctuation acquisition pfizer inc consumer healthcare business net relate divestiture increase total sale growth operational growth total consumer segment overthecounter otc pharmaceutical nutritional franchise sale billion increase attributable new product acquisition strong sale growth achieve analgesic splenda product positive impact otc pharmaceutical nutritional total sale growth newly acquire brand pfizer inc fiscal year company announce voluntary withdrawal certain infant cough cold product market direct medicine generally recognize safe effective assessment available datum use pediatric cough cold medicine identify rare instance misuse lead overdose particularly infant year age product children cough cold product generally subject recent food drug administration fda nonprescription drug advisory committee hearing recommend fda certain change market major consumer franchise sale change dollar million vs vs otc pharmaceutical nutritional skin care baby care womens health oral care total prior year amount reclassify conform current presentation management discussion analysis result operation financial condition sale product action expect significant impact sale otc pharmaceutical nutritional franchise skin care franchise sale billion represent increase increase primarily sale growth suncare clean clear aveeno neutrogena product line new product relate acquisition positive impact skin care total sale growth newly acquire brand pfizer inc fiscal year baby care franchise sale grow billion strong growth lead success cleanser haircare lotion cream powder product line additional contributor growth new product relate acquisition positive impact baby care total sale growth newly acquire brand pfizer inc divestiture relate acquisition fiscal year women health franchise sale grow billion growth primarily newly acquire brand pfizer inc positive impact womens health total sale growth newly acquire brand pfizer inc fiscal year oral care franchise sale grow billion strong sale growth attributable new product acquisition newly launch product listerine mouthwashe dissolvable whitening strip positive impact oral care total sale growth newly acquire brand pfizer inc divestiture relate acquisition consumer segment sale billion increase operational growth account total growth positive currency fluctuation consumer segment sale billion increase international sale billion increase result operation currency fluctuation pharmaceutical segment pharmaceutical segment sale billion increase change operational growth remain increase relate positive impact currency fluctuation pharmaceutical segment sale billion increase international pharmaceutical segment sale billion increase include operational growth relate positive impact currency fluctuation antipsychotic franchise achieve sale billion increase prior year antipsychotic franchise include risperdal oral risperidone medication treat symptom schizophrenia bipolar mania irritability associate autistic behavior indicate patient risperdal consta risperidone long act injectable invega paliperdone extendedrelease tablet treatment schizophrenia sale growth positively impact continued global success risperdal consta patent risperdal compound expire major market outside march fda grant pediatric exclusivity risperdal extend marketing exclusivity risperdal oral end june sale risperdal oral billion loss market exclusivity risperdal oral likely result significant reduction sale remicade infliximab biologic approve treatment crohns disease ankylose spondylitis psoriasis psoriatic arthritis ulcerative colitis use treatment rheumatoid arthritis achieve sale billion growth prior year growth drive increase demand expand indication overall market growth remicade receive approval european commission pediatric crohns disease indication remicade compete market experience increase competition new entrant expansion indication exist competitor procrit epoetin alfa eprex epoetin alfa combine sale billion decline compare prior year decline primarily decline market erythropoiesis stimulate agent esa early year center medicare medicaid issue national coverage determination significantly limit reimbursement esa oncology epoetin alfa product subject label change negatively impact future sale label epoetin alfa product review jurisdiction outside major pharmaceutical product revenue change dollar million vs vs antipsychotic remicade infliximab procriteprex epoetin alfa topamax topiramate levaquin floxin levofloxacinofloxacin aciphexpariet rabeprazole sodium duragesic fentanyl transdermal fentanyl transdermal system concerta methylphenidate hci hormonal contraceptive total prior year amount reclassify conform current presentation johnson johnson annual reporttopamax topiramate approve adjunctive monotherapy use epilepsy prophylactic treatment migraine achieve billion sale increase prior year major contributor growth continue success migraine category patent topamax topiramate expire september company target file pediatric extension fda obtain grant market exclusivity march sales topamax billion expiration product patent loss market exclusivity likely result significant reduction sale levaquin levofloxacin floxin ofloxacin achieve combined sale billion represent growth prior year primarily favorable market growth partially offset increase competitive pressure march fda grant pediatric exclusivity levaquin extend marketing exclusivity month june aciphexpariet rabeprazole sodium proton pump inhibitor comarketed eisai co ltd achieve sale billion increase compare prior year growth overall market growth growth outside market growth partially offset increase competition certain region duragesicfentanyl transdermal fentanyl transdermal system sale decline billion reduction decline result impact generic competition major international market generic competition begin january concerta methylphenidate hci product treatment attention deficit hyperactivity disorder achieve sale billion represent increase original concerta patent expire fda approve generic version substitutable concerta party file abbreviate new drug application anda generic version concerta pende approve time hormonal contraceptive franchise sale decline billion reduction ortho evra norelgestrominethinyl estradiol contraceptive patch approve fda experience significant decline sale result label change negative medium coverage concern product safety sale decline result continued generic competition oral contraceptive pharmaceutical sale billion represent growth prior year big contributor increase velcade product treatment multiple myeloma fiscal fourth quarter company record special pretax noncash charge million writedown intangible asset relate natrecor nesiritide product treatment patient acutely decompensate heart failure dyspnea rest minimal activity charge result revise estimate future cash flow product primarily recent decline natrecor sale trend remain unamortized intangible value associate natrecor million end company believe natrecor important clinical option treatment acutely decompensate heart failure product continue market scios inc subsidiary company company launch invega paliperidone extendedrelease tablet europe additionally company launch antibacterial doribax doripenem injection antiretroviral prezista darunavir europe company submit new molecular entity approval paliperidone palmitate schizophrenia ustekinumab cnto psoriasis europe dapoxetine premature ejaculation country europe antibacterial ceftobiprole europe antihiv medication tmc europe tmc approve fda january market intelence etravirine response challenge face pharmaceutical segment company announce restructure initiative note additional information restructure pharmaceutical segment sale billion increase change operational growth remain increase relate positive impact currency pharmaceutical segment sale billion increase international pharmaceutical segment sale billion increase include operational growth relate positive impact currency medical device diagnostic segment medical device diagnostic segment achieve sale billion represent increase prior major medical device diagnostic franchise sale change dollar million vs vs depuy ethicon endosurgery ethicon cordis lifescan vision care orthoclinical diagnostic total management discussion analysis result operation financial condition year operational growth positive impact currency fluctuation sale billion increase international sale billion increase operation positive currency impact depuy franchise achieve billion sale increase prior year growth primarily depuy orthopaedic joint reconstruction product include hip knee product line strong performance achieve mitek sport medicine product ethicon endosurgery franchise achieve sale billion increase major contributor growth continue endocutter sale include product perform bariatric procedure treatment obesity important focus area franchise strong result achieve continued success harmonic scalpel ultrasonic cutting coagulate surgical device strong growth advanced sterilization product line ethicon franchise sale grow achieve billion sale result solid growth hemostasis women health biosurgical mesh product line continue growth suture sale sale cordis franchise billion decline decline reflect low sale cypher sirolimuselute coronary stent increase competition outside global contraction drug elute stent market follow report potential risk late stent thrombosis associate use drugelute stent result partially offset strong performance biosense webster neurovascular business response challenge face cordis franchise company announce restructure initiative note additional information restructuring june fda notify cordis item outline warning letter receive april july good manufacturing practice regulation good clinical practice regulation resolve lifescan franchise achieve billion sale increase reflect continued success ultra product line additional contributor growth animas business launch insulin pump year vision care franchise achieve sale billion growth rate prior year growth lead continued success brand acuvue oasys acuvue advance astigmatism acuvue advance day acuvue moist day acuvue define day acuvue astigmatism orthoclinical diagnostic franchise achieve billion sale increase continued global growth immunohematology product line growth immunodiagnostic product line launch chaga screen assay medical device diagnostic segment achieve sale billion represent increase prior year operational growth negative impact currency sale billion increase international sale billion increase operation negative currency impact analysis consolidate earning provision taxis income consolidated earning provision taxis income decrease billion billion compare billion earn low earning primarily restructuring charge writedown natrecor intangible asset increase billion percent sale consolidated earning provision taxis income versus section follow highlight significant component change consolidated earning provision taxis income cost product sell sell marketing administrative expense cost product sell sell marketing administrative expense percent sale follow sale cost product sell percent point increasedecrease prior year sell marketing administrative expense percent point increasedecrease prior year increase percent sale cost product sell primarily impact newly acquire consumer brand increase percent sale sell marketing administrative expense primarily impact newly acquire consumer brand partially offset cost containment effort increase percent sale cost product sell unfavorable product mix high manufacturing cost pharmaceutical consumer segment decrease percent sale sell marketing administrative expense result leverage selling expense reduction advertising promotional spending decrease percent sale cost product sell low manufacturing cost primarily related cypher sirolimuselute coronary stent ongoing cost containment activity organization partially offset negative impact pharmaceutical product mix decrease percent sale sell marketing administrative expense cost containment initiative pharmaceutical segment partially offset increase investment spend medical device diagnostic segment research development research development activity represent significant company business expenditure relate development new product improvement exist product technical support product compliance governmental regulation protection consumer patient worldwide cost research johnson johnson annual reportactivitie exclude inprocess research development charge follow dollar million research development expense percent increase prior year percent sale research development expense percent sale pharmaceutical segment research development expense percent sale medical device diagnostic segment research development expense percent sale consumer segment research development activity pharmaceutical segment increase billion compound annual growth rate approximately fiveyear period increase investment research development segment demonstrate company focus knowledgebase product reflect significant number project latestage development restructure company announce initiative expect generate pretax annual cost saving billion effort improve overall cost structure company record million relate pretax charge action take offset anticipate negative impact associate generic competition pharmaceutical segment challenge drugelute stent market company pharmaceutical segment reduce cost base consolidate certain operation continue invest recently launch product latestage pipeline new product cordis franchise move integrate business model address market change underway drugeluting stent well serve broad spectrum patient cardiovascular need reduce cost base program allow company accelerate step standardize streamline certain aspect enterprisewide function human resource finance information technology support growth business leverage scale effectively area procurement benefit operating company note detail inprocess research development company record charge inprocess research development iprd million tax relate acquisition conor medsystems inc iprd charge include operate profit medical device diagnostic segment company record iprd charge million tax relate acquisition consumer healthcare business pfizer inc vascular control systems inc ensure medical inc colbar lifescience ltd hand innovation llc future medical system sa consumer healthcare business pfizer inc account million tax iprd charge include operate profit consumer segment iprd charge follow acquisition include operate profit medical device diagnostic segment vascular control systems inc privately hold company focus develop medical device treat fibroid control bleed obstetric gynecologic application account million tax iprd charge ensure medical inc privately hold company develop device postcatheterization closure femoral artery account million tax iprd charge colbar lifescience ltd privately hold company specialize reconstructive medicine tissue engineering account million tax iprd charge hand innovation llc privately hold manufacturer fracture fixation product upper extremity account million tax iprd charge future medical system sa privately hold company primarily develop manufacture market arthroscopic fluid management system account million tax iprd charge company record iprd charge million tax relate acquisition transform pharmaceuticals inc closure medical corporation peninsula pharmaceuticals inc international commercial right certain patent knowhow field sedation analgesia scott lab inc transform pharmaceuticals inc company specialize discovery superior formulation novel crystalline form drug molecule account million tax iprd charge include operate profit pharmaceutical segment closure medical corporation company expertise intellectual property biosurgical market account million tax iprd charge include operate profit medical device diagnostic segment peninsula pharmaceuticals inc biopharmaceutical company focus develop commercialize antibiotic treat lifethreatening infection account million tax iprd charge include operate profit pharmaceutical segment million tax iprd charge relate scott lab inc refer include operate profit medical device diagnostic segment income expense net income expense net include gain loss relate sale writedown certain investment equity security hold johnson johnson development corporation gain loss disposal property plant equipment currency gain loss minority interest litigation settlement liabilitie royalty income change income expense net increase expense million income expense net include charge million tax relate natrecor intangible asset writedown gain million associate guidant acquisition agreement termination fee associate expense include addition include expense associate record additional product liability reserve integration cost associate acquisition consumer healthcare business pfizer inc income expense net include royalty income partially offset expense item individually significant management discussion analysis result operation financial condition operate profit segment operating profit segment business follow percent segment sale dollar million consumer pharmaceutical med devices diag total expensesincome allocate segment earning provision taxis income note detail amount allocate segment include interest incomeexpense minority interest general corporate incomeexpense bar graph consumer segment consumer segment operating profit increase percent sale operating profit increase iprd expense million expense associate consumer healthcare business pfizer inc integration record consumer segment operating profit decrease percent sale decline prior year result million iprd expense expense associate consumer healthcare business pfizer inc integration record pharmaceutical segment pharmaceutical segment operating profit decrease percent sale operating profit decrease result million restructuring charge million natrecor intangible asset writedown pharmaceutical segment operating profit increase percent sale increase prior year increase result million iprd record partially offset increase research development spending low gross margin medical device diagnostic segment operating profit medical device diagnostic segment decrease percent sale operating profit decrease result million iprd expense million restructuring charge include gain associate guidant acquisition agreement termination fee associate expense million medical device diagnostic segment operating profit increase percent sale increase prior year primary driver improve operating profit guidant acquisition agreement termination fee associate expense million record partially offset high iprd charge million versus million addition advertise promotional expense leverage offset increase research development spending interest income expense interest income decrease million low average cash balance decline average cash balance primarily acquisition consumer healthcare business pfizer inc december cash balance include marketable security billion end average billion compare billion average cash balance interest expense increase million high average debt balance net debt balance end billion compare billion end high debt balance debt associate acquisition consumer healthcare business pfizer inc common stock repurchase program interest income increase million primarily high rate interest high average cash balance despite billion common stock repurchase program increase acquisition activity compare prior year cash balance include current marketable security billion end average billion compare billion average cash balance interest expense increase slightly compare high average debt balance billion billion partially offset decrease interest rate interest income increase million primarily high rate interest high average cash balance cash balance include current marketable security billion end average billion compare billion average cash balance provision taxis income worldwide effective income tax rate tax rate benefit onetime gain million relate international business restructure certain country increase taxable income low tax jurisdiction relative taxable income high tax jurisdiction low international tax rate certain country tax rate increase compare primarily gain million record partially offset benefit relate reversal tax allowance million associate international business effective tax rate benefit previously mention million reversal tax liability previously record fiscal fourth quarter relate technical correction american jobs creation act liquidity capital resource cash flow cash flow operation billion increase billion billion increase cash flow operation primarily attributable noncash expense associate natrecor intangible asset writedown johnson johnson annual reportand increase depreciation amortization net cash investing activity billion versus billion include acquisition consumer healthcare business pfizer inc detailed discussion merger acquisition note billion net increase purchase investment primarily marketable security capital expenditure billion billion billion respectively net cash financing activity decrease billion primarily billion decrease repurchase common stock billion increase proceed exercise stock option partially offset billion decrease proceed short longterm debt billion increase dividend shareholder cash current marketable security billion end compare billion end primarily cash flow operation cash generate operation amount billion billion cash generate operation billion major factor contribute increase net income increase billion net noncash impact iprd charge billion increase account payable accrue liability partially offset billion increase defer taxis billion increase current noncurrent asset bar graph finance market risk company use financial instrument manage impact foreign exchange rate change cash flow accordingly company enter forward foreign exchange contract protect value certain foreign currency asset liability hedge future foreign currency product cost gain loss contract offset gain loss underlie transaction appreciation dollar december market rate increase unrealized value company forward contract million conversely depreciation dollar december market rate decrease unrealized value company forward contract million scenario gain loss forward contract offset gain loss underlie transaction impact future earning cash flow company hedge exposure fluctuation currency exchange rate effect certain asset liability foreign currency enter currency swap contract change spread foreign interest rate companys interest rate sensitive financial instrument increase decrease unrealized value company swap contract approximately million scenario maturity gain loss swap contract offset gain loss underlie transaction impact future cash flow company enter financial instrument trade speculative purpose company policy enter contract party equivalent credit rating counterpartie contract major financial institution significant concentration exposure counterparty management believe risk loss remote total credit available company approximate billion billion expire september billion expire september total borrowing end billion billion respectively increase borrowing result finance general corporate purpose common stock repurchase program net debt cash current marketable security net debt billion compare net debt billion total debt represent total capital shareholder equity total debt total capital shareholder equity share end compare yearend increase period end december material cash commitment johnson johnson continue industrial company triple credit rating summary borrowing find note management discussion analysis result operation financial condition contractual obligation commitment company contractual obligation primarily lease debt obligation unfunded retirement plan significant obligation satisfy obligation company use cash operation follow table summarize company contractual obligation aggregate maturity december note audit consolidated financial statement detail unfunded operate debt retirement dollar millions lease obligation plan total total amount include interest expense tax matter note share repurchase dividend july company announce board director approve stock repurchase program authorize company buy billion company common stock repurchase program time limit suspend period discontinue time share acquire available general corporate purpose company intend fund share repurchase program combination available cash debt company repurchase aggregate million share johnson johnson common stock current repurchase program cost billion addition company annual program repurchase share use employee stock incentive plan company increase dividend th consecutive year cash dividend pay share compare dividend share share dividend distribute follow quarter second quarter quarter fourth quarter total january board director declare regular cash dividend share payable march shareholders record february company expect continue practice pay regular cash dividend information critical accounting policy estimate management discussion analysis result operation financial condition base company consolidate financial statement prepare accordance accounting principle generally accept preparation financial statement require management estimate assumption affect amount report revenue expense asset liability relate disclosure actual result differ estimate company believe understand certain key accounting policy estimate essential achieve insight company operating result financial condition key accounting policy include revenue recognition income taxis legal selfinsurance contingency valuation longlive asset assumption determine amount record pension employee benefit plan account stock option revenue recognition company recognize revenue product sale good ship deliver title risk loss pass customer provision certain rebate sale incentive trade promotion coupon product return discount customer account reduction sale period relate sale record product discount grant base term arrangement direct indirect market participant market condition include price charge competitor rebate large medicaid rebate provision estimate base sale term historical experience trend analysis project market condition market serve company evaluate market condition product group product primarily analysis wholesaler party sellthrough market research datum internally generate information sale return generally estimate record base historical sale return information product exhibit unusual sale return pattern date competition marketing matter specifically investigate analyze accounting sale return accrual sale return allowance represent reserve product return expiration destruction field specific area product recall return reserve base historical return trend product market percent gross sale promotional program product list allowance cooperative advertising arrangement record year incur continue promotional program include coupon volumebase sale incentive program redemption cost consumer coupon base historical redemption experience product value volumebase incentive program derive estimate sale volume incentive period record product sell promotional arrangement contain customer acceptance criterion evaluate determine appropriate amount defer addition company enter collaboration arrangement contain multiple revenue generating activity revenue arrangement recognize activity perform deliver base relative fair value upfront fee receive arrangement performance obligation exist recognize revenue early receipt payment collection assure performance obligation exist company defer upfront fee recognize earn obligation period johnson johnson annual reportreasonably likely change assumption calculate accrual rebate return promotion anticipate material effect financial statement company currently disclose impact change assumption quarterly annual file financial statement impact table progression accrue rebate return promotion reserve doubtful account reserve cash discount segment business year end december december consumer segment balance balance beginning payment end dollar million period accrual period accrue rebate accrue return accrue promotions subtotal reserve doubtful account reserve cash discount total accrue rebate accrue return accrue promotions subtotal reserve doubtful account reserve cash discount total include reserve customer rebate million december million december record contra asset pharmaceutical segment balance balance beginning payment end dollar million period accrual period accrue rebate accrue return accrue promotions subtotal reserve doubtful account reserve cash discount total accrue rebate accrue return accrue promotions subtotal reserve doubtful account reserve cash discount total include reserve customer rebate million december million december record contra asset medical device diagnostic segment balance balance beginning payment end dollar million period accrual period accrue rebate accrue return accrue promotions subtotal reserve doubtful account reserve cash discount total accrue rebate accrue return accrue promotions subtotal reserve doubtful account reserve cash discount total include reserve customer rebate million december million december record contra asset company earn service revenue copromotion certain product year present service revenue total revenue include sale customer income taxis income taxis record base amount refundable payable current year include result difference gaap accounting tax reporting record defer tax asset liability company estimate defer tax asset liability base current tax regulation rate change tax law rate affect record defer tax asset liability future management believe change estimate material effect company result operation cash flow financial position company adopt fasb interpretation fin accounting uncertainty income taxis interpretation fasb statement interpretation prescribes recognition threshold measurement attribute financial statement recognition measurement tax position take expect take tax return interpretation provide guidance derecognition classification matter note information income taxis december december cumulative amount undistribute international earning approximately billion billion respectively company intend continue reinv undistributed international earning expand international operation tax expense record cover undistribute portion intend repatriation management discussion analysis result operation financial condition legal self insurance contingency company record accrual contingency include legal proceeding product liability case arise normal course business accrual base management judgment probability loss opinion legal counsel applicable actuarially determined estimate additionally company record insurance receivable amount thirdparty insurer recovery probable appropriate reserve receivables record estimate amount collect thirdparty insurer longlive intangible asset company assess change economic condition make assumption estimate future cash flow evaluate value company property plant equipment goodwill intangible asset assumption estimate change time necessary company record impairment charge employee benefit plan company sponsor retirement pension plan include define benefit define contribution termination indemnity plan cover employee worldwide plan base assumption discount rate expect return plan asset expect salary increase health care cost trend rate note detail rate effect rate change companys result operation stock option fiscal quarter company adopt statement financial accounting standard sfas r share base payment company apply modify retrospective transition method implement sfas r previously report financial statement restate accordance provision sfas r note information stock option new accounting pronouncement june financial accounting standard board fasb issue fasb interpretation fin accounting uncertainty income taxis interpretation fasb statement interpretation prescribes recognition threshold measurement attribute financial statement recognition measurement tax position take expect take tax return interpretation provide guidance derecognition classification matter fin effective fiscal year company adopt quarter september fasb issue sfas fair value measurement statement define fair value establishe framework measure fair value generally accept accounting principle expand disclosure fair value measurement statement effective fiscal quarter nonfinancial asset liability recognize disclose fair value recur basis effective date fiscal year begin november company believe adoption sfas material effect result operation cash flow financial position february fasb issue sfas fair value option financial asset financial liability permit entity measure certain financial asset financial liability fair value sfas effective fiscal year company adopt accordingly company assess impact adoption sfas currently believe adoption material impact result operation cash flow financial position december fasb issue sfas r business combination noncontrolle interest consolidate financial statement statement aim improve simplify converge internationally account business combination report noncontrolle interest consolidate financial statement statement effective fiscal year begin december sfas r significant impact manner company account future acquisition begin fiscal year significant change include capitalization iprd expensing acquisition relate restructuring action transaction relate cost recognition contingent purchase price consideration fair value acquisition date company believe adoption sfas r sfas material effect result operation cash flow financial position eitf issue account collaborative arrangement relate development commercialization intellectual property issue effective financial statement issue fiscal year begin december issue address income statement classification payment party collaborative arrangement adoption eitf expect significant impact company result operation cash flow financial position eitf issue account nonrefundable advance payment good service receive use future research development activity issue effective financial statement issue fiscal year begin december issue require nonrefundable advance payment research development capitalize recognize expense relate good deliver service perform adoption eitf expect significant impact company result operation cash flow financial position economic market factor company aware product environment decade policymaker consumer business express concern rise cost health care response concern company longstande policy pricing product responsibly period united states weight average compound annual growth rate company net price increase health care product prescription overthecounter drug hospital professional product consumer price index cpi inflation rate moderate part world continue effect worldwide economy consequently way company operate face increase cost company strive maintain profit margin cost reduction program productivity improvement periodic price increase company face worldwide health care change result pricing pressure include health care cost containment government legislation relate sale promotion reimbursement johnson johnson annual reportthe company operate environment increasingly hostile intellectual property right generic drug firm file anda seek market generic form company key pharmaceutical product prior expiration applicable patent cover product event company successful defend patent claim challenge anda filing generic firm introduce generic version product issue result potential substantial market share revenue loss product information discussion litigation filer abbreviate new drug application note legal proceeding company involve numerous product liability case unite states concern adverse reaction drug medical device damage claim substantial company confident adequacy warning instruction use accompany product feasible predict ultimate outcome litigation company believe liability result case substantially cover exist amount accrue company balance sheet selfinsurance program thirdparty product liability insurance company involve number patent trademark lawsuit investigation incidental business ultimate legal financial liability company respect claim lawsuit proceeding refer estimate certainty company opinion base examination matter experience date discussion counsel ultimate outcome legal proceeding net liability accrue company balance sheet expect material adverse effect company financial position resolution report period matter significant impact company result operation cash flow period note information legal proceeding common stock market price company common stock list new york stock exchange symbol jnj composite market price range johnson johnson common stock high low high low quarter second quarter quarter fourth quarter yearend close cautionary factor affect future result annual report contain forwardlooke statement forwardlooke statement relate strictly historical current fact anticipate result base management plan subject uncertainty forwardlooke statement identify use word plan expect anticipate estimate word similar meaning conjunction thing discussion future operation financial performance company strategy growth product development regulatory approval market position expenditure forwardlooke statement base current expectation future event company guarantee forwardlooke statement accurate company believe reasonable expectation assumption investor realize underlying assumption prove inaccurate unknown risk uncertainty materialize actual result vary materially company expectation projection investor caution place undue reliance forwardlooke statement company undertake update forwardlooke statement result new information future event development risk uncertainty include general industry condition competition economic condition interest rate currency exchange rate fluctuation technological advance new product patent attain competitor challenge inherent new product development include obtain regulatory approval challenge patent foreign health care reform governmental law regulation trend health care cost containment increase scrutiny health care industry government agency product efficacy safety concern result product recall regulatory action company report year end december include exhibit discussion additional factor cause actual result differ expectation company note factor permit private security litigation reform act management discussion analysis result operation financial condition consolidated balance sheet johnson johnson subsidiaries december december dollar million share share datum note asset current asset cash cash equivalent note marketable security note account receivable trade allowance doubtful account inventory note defer taxis income note prepay expense receivables total current asset marketable security noncurrent note property plant equipment net note intangible asset net note goodwill net note defer taxis income note asset note total asset liability shareholder equity current liability loan note payable note account payable accrue liability accrue rebate return promotions accrue salary wages commission accrue taxis income total current liability longterm debt note defer taxis income note employee relate obligation note liability total liability shareholder equity prefer stock par value authorize unissued share common stock par value share note authorize share issue share accumulate comprehensive income note retain earning common stock hold treasury cost note share share total shareholder equity total liability shareholder equity note consolidated financial statement johnson johnson annual reportconsolidate statement earnings johnson johnson subsidiarie dollar million share figure note sale customer cost product sell gross profit selling marketing administrative expense research expense purchase inprocess research development note restructure note interest income interest expense net portion capitalize note income expense net earning provision taxis income provision taxis income note net earning basic net earning share note dilute net earning share note note consolidated financial statement consolidate financial statement consolidate statement equity johnson johnson subsidiary note receivable accumulate employee treasury comprehensive retain stock ownership comprehensive common stock stock dollar million note total income earning plan esop income issue balance january net earning cash dividend pay employee stock compensation stock option plan conversion subordinate debenture repurchase common stock comprehensive income net tax currency translation adjustment unrealize loss security employee benefit plan gain derivative hedge reclassification adjustment total comprehensive income note receivable esop balance january net earning cash dividend pay employee compensation stock option plan conversion subordinate debenture repurchase common stock comprehensive income net tax currency translation adjustment unrealize loss security employee benefit plan loss derivative hedge reclassification adjustment total comprehensive income balance december net earning cash dividend pay employee compensation stock option plan conversion subordinate debenture repurchase common stock adoption fin comprehensive income net tax currency translation adjustment unrealize gain security employee benefit plan loss derivative hedges reclassification adjustment total comprehensive income balance december note consolidated financial statement johnson johnson annual reportconsolidate statement cash flow johnson johnson subsidiaries dollar million note cash flow operating activity net earning adjustment reconcile net earning cash flow depreciation amortization property intangible stock base compensation purchase inprocess research development intangible asset writedown natrecor defer tax provision account receivable allowance change asset liability net effect acquisition increase account receivable decreaseincrease inventory increasedecrease account payable accrue liability increasedecrease current noncurrent asset increase current noncurrent liability net cash flow operating activity cash flow invest activity addition property plant equipment proceed disposal asset acquisition net cash acquire note purchase investment sale investment primarily intangible net cash investing activity cash flow financing activity dividend shareholder repurchase common stock proceed shortterm debt retirement shortterm debt proceed longterm debt retirement longterm debt proceed exercise stock optionsexcess tax benefit net cash financing activity effect exchange rate change cash cash equivalent decreaseincrease cash cash equivalent cash cash equivalent begin year note cash cash equivalent end year note supplemental cash flow datum cash pay year interest income taxis supplemental schedule noncash investing financing activity treasury stock issue employee compensation stock option plan net cash proceed conversion debt acquisition fair value asset acquire fair value liability assume net cash pay acquisition note consolidated financial statement consolidated financial statement note consolidated financial statement summary significant accounting policy principle consolidation consolidated financial statement include account johnson johnson subsidiaries company intercompany account transaction eliminate description company business segment company approximately employee worldwide engage research development manufacture sale broad range product health care field company conduct business virtually country world primary focus product relate human health wellbee company organize business segment consumer pharmaceutical medical device diagnostic consumer segment manufacture market broad range product baby care skin care oral care wound care womens health care field nutritional overthecounter pharmaceutical product product market principally general public sell wholesaler directly independent chain retail outlet world pharmaceutical segment include product follow therapeutic area antiinfective antipsychotic cardiovascular contraceptive dermatology gastrointestinal hematology immunology neurology oncology pain management urology virology product distribute directly retailer wholesaler health care professional prescription use general public medical device diagnostic segment include broad range product principally professional field physician nurse therapist hospital diagnostic laboratory clinic product include cordis circulatory disease management product depuy orthopaedic joint reconstruction spinal care product ethicon wound care women health product ethicon endosurgerys minimally invasive surgical product lifescan blood glucose monitor insulin delivery product orthoclinical diagnostic professional diagnostic product vision care disposable contact lense new accounting pronouncement june financial accounting standard board fasb issue fasb interpretation fin accounting uncertainty income taxis interpretation fasb statement interpretation prescribes recognition threshold measurement attribute financial statement recognition measurement tax position take expect take tax return interpretation provide guidance derecognition classification matter fin effective fiscal year company adopt quarter september fasb issue statement financial accounting standard sfas fair value measurement statement define fair value establishe framework measure fair value generally accept accounting principle expand disclosure fair value measurement statement effective fiscal quarter nonfinancial asset liability recognize disclose fair value recur basis effective date fiscal year begin november company believe adoption sfas material effect result operation cash flow financial position february fasb issue sfas fair value option financial asset financial liability permit entity measure certain financial asset financial liability fair value sfas effective fiscal year company adopt accordingly company assess impact adoption sfas currently believe adoption material impact result operation cash flow financial position december fasb issue sfas r business combination noncontrolle interest consolidate financial statement statement aim improve simplify converge internationally account business combination report noncontrolle interest consolidate financial statement statement effective fiscal year begin december sfas r significant impact manner company account future acquisition begin fiscal year significant change include capitalization iprd expensing acquisition relate restructuring action transaction relate cost recognition contingent purchase price consideration fair value acquisition date company believe adoption sfas r sfas material effect result operation cash flow financial position eitf issue account collaborative arrangement relate development commercialization intellectual property issue effective financial statement issue fiscal year begin december issue address income statement classification payment party collaborative arrangement adoption eitf expect significant impact company result operation cash flow financial position eitf issue account nonrefundable advance payment good service receive use future research development activity issue effective financial statement issue fiscal year begin december issue require nonrefundable advance payment research development capitalize recognize expense relate good deliver service perform adoption eitf expect significant impact company result operation cash flow financial position cash equivalent company consider security maturity month purchase cash equivalent investment shortterm marketable security carry cost approximate fair value investment classified availableforsale carry estimate fair value unrealize gain loss record component accumulate comprehensive income longterm debt security company ability intent hold maturity carry amortize cost approximate fair value management determine appropriate classification investment debt equity security time purchase reevaluate determi johnson johnson annual reportnation balance sheet date company periodically review investment equity security impairment adjust investment fair value decline market value deem temporary property plant equipment depreciation property plant equipment state cost company utilize straightline method depreciation estimate useful life asset building building equipment year land leasehold improvement year machinery equipment year company capitalize certain computer software development cost include machinery equipment incur connection develop obtain computer software internal use capitalize software cost amortize estimate useful life software generally range year company review longlive asset assess recoverability undiscounted cash flow necessary charge impairment longlive asset record present value future cash flow carry value asset revenue recognition company recognize revenue product sale good ship deliver title risk loss pass customer provision certain rebate sale incentive trade promotion product return discount customer account reduction sale period relate sale record product discount grant base term arrangement direct indirect market participant market condition include price charge competitor rebate large medicaid rebate provision estimate base sale term historical experience trend analysis project market condition market serve company evaluate market condition product group product primarily analysis wholesaler party sellthrough market research datum internally generate information sale return generally estimate record base historical sale return information product exhibit unusual sale return pattern date competition marketing matter specifically investigate analyze accounting sale return accrual sale return allowance represent reserve product return expiration destruction field specific area product recall return reserve base historical return trend product market percent gross sale promotional program product list allowance cooperative advertising arrangement record year incur continue promotional program include coupon volumebase sale incentive program redemption cost consumer coupon base historical redemption experience product value volumebase incentive program base estimate sale volume incentive period record product sell company earn service revenue copromotion certain product include sale customer promotional arrangement contain customer acceptance criterion evaluate determine appropriate amount defer addition company enter collaboration arrangement contain multiple revenue generating activity revenue arrangement recognize activity perform deliver base relative fair value upfront fee receive arrangement performance obligation exist recognize revenue early receipt payment collection assure performance obligation exist company defer upfront fee recognize earn obligation period shipping handle shipping handling cost incur million million million respectively include sell marketing administrative expense revenue receive shipping handle sale customer period present inventory inventory state low cost market determine firstin firstout method intangible asset goodwill sfas require goodwill nonamortizable intangible asset assess annually impairment company complete annual impairment test fiscal fourth quarter impairment determine future impairment test perform annually fiscal fourth quarter soon trigger event occur intangible asset finite useful life continue amortize useful life review impairment warrant economic condition note detail intangible asset financial instrument company follow provision sfas accounting derivative instrument hedge activity amend sfas require derivative instrument record balance sheet fair value change fair value derivative record period current earning comprehensive income depend derivative designate hedge transaction type hedge transaction company use forward exchange contract manage exposure variability cash flow primarily relate foreign exchange rate change future intercompany product party purchase raw material denominate foreign currency company use currency swap manage currency risk primarily relate borrowing type derivative designate cash flow hedge additionally company use forward exchange contract offset exposure certain foreign currency asset liabilitie forward exchange contract designate hedge change fair value derivative recognize earning offset current earning effect relate foreign currency asset liability designation cash flow hedge entrance date derivative contract inception derivative expect highly effective change fair value derivative designate cash flow hedge highly effective record accumulate comprehensive note consolidated financial statement income underlie transaction affect earning reclassify earning account hedge transaction fair value derivative instrument ie forward foreign exchange contract currency swap aggregation currency future cash flow discount present value prevail market interest rate subsequently convert dollar current spot foreign exchange rate ongoing basis company assess derivative continue highly effective offset change cash flow hedge item derivative long expect highly effective hedge accounting discontinue hedge ineffectiveness include current period earning insignificant company document relationship hedge item derivative overall risk management strategy include reason undertake hedge transaction enter derivative objective strategy minimize foreign currency exposure impact company financial performance protect company cash flow adverse movement foreign exchange rate ensure appropriateness financial instrument manage enterprise risk associate financial institution product liability accrual product liability claim record undiscounted basis probable liability incur liability reasonably estimate base exist information accrual adjust periodically additional information available result cost availability factor effective november company cease purchase thirdparty product liability insurance base availability prior coverage receivables insurance recovery relate product liability claim record undiscounted basis probable recovery realize research development research development expense expense incurred upfront milestone payment party connection research development collaboration expense incur point regulatory approval payment party subsequent regulatory approval capitalize amortize remain useful life relate product amount capitalize payment include intangible net accumulate amortization advertising cost associate advertising expense year incur include sell marketing administrative expense advertising expense worldwide comprise television radio print medium internet advertising billion billion billion income taxis company intend continue reinv undistributed international earning expand international operation tax expense record cover undistribute portion intend repatriation december december cumulative undistribute international earning approximately billion billion respectively defer income taxis recognize tax consequence temporary difference apply enact statutory tax rate applicable future year difference financial reporting tax basis exist asset liability net earning share basic earning share compute divide net earning available common shareholder weight average number common share outstanding period dilute earning share reflect potential dilution occur security exercise convert common stock treasury stock method use estimate preparation consolidate financial statement conformity accounting principle generally accept require management estimate assumption affect amount report estimate accounting sale discount rebate allowance incentive product liability income taxis depreciation amortization employee benefit contingency intangible asset liability valuation instance determine annual pension postemployment benefit cost company estimate rate return plan asset cost future health care benefit actual result differ estimate annual closing date company follow concept fiscal year end sunday nearest end month december normally fiscal year consist week year fiscal year consist week inventory end inventory comprise dollar million raw material supply good process finish good property plant equipment end property plant equipment cost accumulate depreciation dollar million land land improvement building build equipment machinery equipment construction progress accumulate depreciation company capitalize interest expense cost construction facility equipment interest expense capitalize million million million respectively depreciation expense include amortization capitalize interest billion billion billion respectivelyupon retirement disposal property plant equipment cost relate amount accumulate depreciation johnson johnson annual reportor amortization eliminate asset accumulate depreciation account respectively difference net asset value proceed record earning rental expense lease commitment rental space vehicle manufacture equipment office datum processing equipment operating lease approximately million million million approximate minimum rental payment require operating lease initial remain noncancelable lease term excess year december dollar million total commitment capital lease significant employee relate obligation end employee relate obligation dollar million pension benefit postretirement benefit postemployment benefit defer compensation current benefit payable employee relate obligation prepay employee relate obligation million million respectively include asset consolidate balance sheet borrowing component longterm debt follow effective effective dollar million rate rate zero coupon convertible subordinated debenture debenture debenture note debenture note debenture note note gbp note b euro debenture include industrial revenue bond current portion weight average effective rate translation rate december company access substantial source fund numerous bank worldwide total credit available company approximate billion billion expire september billion expire september interest charge borrowing credit line agreement base bid provide bank prime rate london interbank offer rate libor plus applicable margin commitment fee agreement material company file shelf registration security exchange commission effective november enable company issue billion debt security warrant purchase debt security company issue bond august total billion november total billion general corporate purpose common stock repurchase program december company billion remain shelf registration july alza corporation subsidiary company complete private offering zero coupon convertible subordinated debenture issue price principal maturity december outstanding debenture total principal maturity million yield maturity annum compute semiannual bond equivalent basis periodic interest payment term debenture holder entitle convert debenture approximately million share johnson johnson common stock price share approximately million share issue december voluntary conversion note holder option holder debenture repurchase company july purchase price equal issue price plus accrete original issue discount purchase date company option elect deliver johnson johnson common stock cash combination stock cash event repurchase debenture company option redeem debenture july issue price plus accrete original issue discount december december fair value base quote market value debenture million million respectively shortterm borrowing current portion longterm debt amount approximately billion end billion raise commercial paper program remainder represent principally local borrowing international subsidiary aggregate maturity longterm obligation commence dollar million certain business relationship member company board director chief executive officer major bank bank provide service company payment significant company bank company plan engage bank provide note consolidated financial statement service include investment banking service company company anticipate payment service significant bank company intangible asset goodwill end gross net amount intangible asset goodwill dollar million trademark nonamortizable gross accumulate amortization trademark nonamortizable net patent trademark gross accumulate amortization patent trademark net intangible gross accumulate amortization intangible net subtotal intangible asset gross accumulate amortization subtotal intangible asset net goodwill gross accumulate amortization goodwill net total intangible asset goodwill gross accumulate amortization total intangible asset goodwill net goodwill december december allocate segment business follow med dev dollar million consumer pharm diag total goodwill january acquisition translationother goodwill december acquisition translationother goodwill december weight average amortization period patent trademark intangible asset year year respectively amortization expense amortizable intangible asset fiscal year end december december january million million million tax respectively certain patent intangible asset write fair value fiscal year result charge include amortization expense reduction total patent trademark compare primarily writedown million tax relate natrecor intangible asset remain unamortized intangible value associate natrecor million end charge result revise estimate future cash flow product primarily recent decline natrecor sale trend natrecor continue market scios inc subsidiary company estimate amortization expense succeed year approximate million tax year substantially amortization expense include cost product sell income taxis provision taxis income consist dollar million currently payable tax international taxis defer taxis international taxis comparison income tax expense statutory rate company effective tax rate follow dollar million international earning taxis income tax ratesus statutory rate puerto rico ireland operation research orphan drug tax credit state local international subsidiary exclude ireland technical corrections act impact tax liability manufacture deduction process research development iprd tax international income effective tax rate company subsidiary manufacture ireland incentive tax rate addition company subsidiary operate puerto rico tax incentive grant possession tax credit expire apply certain operation puerto rico decrease tax rate mainly attribute increase taxable income low tax jurisdiction relative taxable income high jurisdiction low international tax rate certain country international tax rate benefit business restructure certain international subsidiary result onetime benefit million reduce effective tax rate johnson johnson annual reportthe increase tax rate mainly reversal tax liability million report tax provision result technical correction american jobs creation act partially offset benefit report reversal tax allowance million associate international business temporary difference carry forwards follow defer tax defer tax dollar million asset liability asset liability employee relate obligation stock base compensation depreciation nondeductible intangible international rd capitalize tax reserve liabilitie income report tax purpose miscellaneous international capitalize intangible miscellaneous total deferred income taxis difference net defer tax income balance sheet net defer tax include taxis income balance sheet company adopt fin accounting uncertainty income taxis effective january result recognition additional million previously unrecognized tax benefit correspond adjustment retain earning company billion gross unrecognized tax benefit billion net unrecognized tax benefit january include previous adjustment mention company classifie liabilities unrecognize tax benefit relate interest penalty longterm liabilitie interest expense penalty relate unrecognized tax benefit classify income tax expense year end december company recognize million interest income million interest expense aftertax impact million total accrue interest million million respectively follow table summarize activity relate unrecognized tax benefit dollar million total balance january increase relate current year tax position increase relate prior period tax position decrease relate prior period tax position settlement lapse statute limitation balance december include unrecognized tax benefit approximately billion december billion potential tax benefit recognize affect company annual effective tax rate company conduct business file tax return numerous country currently tax audits progress number tax authority internal revenue service irs complete audit tax year year remain open limit number issue consider irs appeal level company expect resolve month major jurisdiction company conduct business year remain open generally year jurisdiction remain open far company expect total unrecognized tax benefit significantly change month company expect significant payment month able provide reasonably reliable estimate time future tax payment relate uncertain tax position international currency translation translation subsidiary operate nonus dollar currency company determine local currency international subsidiary functional currency highly inflationary economy define compound cumulative rate inflation past year substantial portion cash flow local currency consolidate international subsidiary balance sheet currency effect record component accumulate comprehensive income equity account include result translate balance sheet asset liability current exchange rate locate highly inflationary economy translation balance sheet account highly inflationary economy reflect operating result analysis change foreign currency translation adjustment include note net currency transaction translation gain loss include income expense loss million million million respectively common stock stock option plan stock compensation agreement stock option december company stockbase compensation plan share outstanding contract company stock option plan longterm incentive plan stock compensation plan nonemployee director plan centocor innovasive device alza inverness scio stock option plan option restrict share grant plan longterm incentive plan compensation cost record sfas r charge income plan million million million total income tax benefit recognize income statement sharebase compensation cost million million million sharebased compensation cost capitalize inventory insignificant period stock option expire year date grant vest service period range month note consolidated financial statement year option grant average high low price company common stock new york stock exchange date grant longterm incentive plan company issue million share common stock share available future grant longterm incentive plan million end company settle employee stock option exercise treasury share treasury share replenish year number share settle employee stock option exercise fair value option award estimate date grant blackschole option valuation model use assumption note follow table start expect volatility represent blend rate year daily historical average volatility rate week average imply volatility rate base atthemoney trade johnson johnson option life year prior expect volatility base year weekly historical volatility rate historical datum determine expect life option riskfree rate base treasury yield curve effect time grant average fair value option grant respectively fair value estimate base weighted average assumption riskfree rate expect volatility expect life yrs yrs yrs dividend yield summary option activity plan december december january change year end date present aggregate weight intrinsic outstanding average value share thousand share exercise price dollar million share january option grant option exercise option canceledforfeite share january option grant option exercise option canceledforfeite share december option grant option exercise option canceledforfeite share december total intrinsic value option exercise million million million respectively total unrecognized compensation cost million december million december million january weight average period cost recognize year year year follow table summarize stock option outstanding exercisable december share thousand outstanding exercisable average average exercise average exercise exercise price range option life price option price average contractual life remain year stock option exercisable december january average price average life year option average price average life year respectively restrict share unit company grant restrict share unit vest period year company settle employee stock issuance treasury share treasury share replenish year number share employee stock issuance summary share activity plan december outstanding share thousand share share january share grant share issue share canceledforfeite share december share grant share issue share canceledforfeite share december average fair value restrict share unit grant respectively fair market value date grant fair value restrict share unit discount dividend pay restricted share unit vest period fair value restrict share unit settle million million respectively johnson johnson annual report segment business geographic area sale customer dollar million consumer united states international total pharmaceutical united states international total medical device diagnostic united states international total worldwide total operating profit identifiable asset dollar million consumer pharmaceutical medical device diagnostic total incomeexpense allocate segment general corporate worldwide total addition property depreciation plant equipment amortization dollar million consumer pharmaceutical medical device diagnostic segment total general corporate worldwide total sale customer longlive asset dollar millions united states europe western hemisphere exclude asiapacific africa segment total general corporate non longlived asset worldwide total note description segment company operate export sale intersegment sale significant company customer represent total revenue amount allocate segment include interest incomeexpense minority interest general corporate incomeexpense general corporate include cash marketable security include million restructure expense comprise million million million consumer pharmaceutical medical device diagnostic segment respectively medical device diagnostic segment include million inprocess research development iprd pharmaceutical segment include million writedown natrecor intangible asset include million million iprd consumer medical device diagnostic segment respectively medical device diagnostic segment include guidant acquisition agreement termination fee associate expense million include million million iprd pharmaceutical medical device diagnostic segment respectively longlive asset include property plant equipment net respectively intangible asset net respectively note consolidated financial statement accumulate comprehensive income component comprehensive incomeloss consist follow total unrealized gain accumulate foreign gain loss currency loss employee derivative comprehensive dollar million translation security benefit plan hedge incomeloss jan changes net change hedging transaction net reclasse net earning net change jan change net change hedging transaction net reclasse net earning net change dec change net change hedging transaction net reclasse net earning net change dec total comprehensive income include reclassification adjustment gain million realize sale equity security associate tax expense million total comprehensive income include reclassification adjustment gain million realize sale equity security associate tax expense million total comprehensive income include reclassification adjustment gain million realize sale equity security associate tax expense million tax effect unrealize gainslosses equity security balance expense million million million respectively tax effect relate employee benefit plan million million million respectively tax effect gainslosse derivative hedge gain million loss million million respectively note additional information relate derivative hedge currency translation adjustment currently adjust income taxis relate permanent investment international subsidiary pension benefit plan company sponsor retirement pension plan include define benefit define contribution termination indemnity plan cover employee worldwide company provide postretirement benefit primarily health care retire employee dependent international employee cover governmentsponsored program cost company significant retirement plan benefit primarily base employee compensation year retirement number year service international subsidiary plan fund deposit trustee annuity purchase group contract reserve provide company fund retiree health care benefit advance right modify plan future company use date consolidate financial statement december december respectively measurement date international retirement benefit plan september statement financial accounting standard sfas employer account define benefit pension postretirement plan issue amend disclosure requirement pension postretirement benefit statement amendment fasb statement r incremental effect apply fasb billion reduction shareholder equity net defer taxis johnson johnson annual reportnet periodic benefit cost company define benefit retirement plan benefit plan include follow component retirement plan benefit plan dollar million service cost interest cost expect return plan asset amortization prior service cost amortization net transition asset recognize actuarial loss curtailment settlement net periodic benefit cost net periodic benefit cost attributable retirement plan million million million amount expect recognize net periodic benefit cost come year company define benefit retirement plan postretirement plan dollar million amortization net transition obligation amortization net actuarial loss amortization prior service cost weightedaverage assumption follow table represent rate develop actuarial present value project benefit obligation year list net periodic benefit cost follow year retirement plan benefit plan dollar million benefit plan discount rate expect longterm rate return plan asset rate increase compensation level international benefit plan discount rate expect longterm rate return plan asset rate increase compensation level company discount rate determine consider current yield curve represent high quality longterm fix income instrument result discount rate consistent duration plan liability expect longterm rate return plan asset assumption determine building block approach consider historical average real return asset class certain country historical return meaningful consideration give local market expectation longterm return follow table display assume health care cost trend rate individual health care plan health care cost trend rate assume year rate cost trend rate assume decline ultimate trend year rate reach ultimate trend rate onepercentagepoint change assume health care cost trend rate follow effect onepercentage onepercentage dollar million point increase point decrease health care plan total interest service cost postretirement benefit obligation note consolidated financial statement follow table set forth information relate benefit obligation fair value plan asset yearend company define benefit retirement plan postretirement plan retirement plan benefit plan dollar million change benefit obligation project benefit obligation begin year service cost interest cost plan participant contribution amendment actuarial gain loss divestiture acquisition curtailment settlement benefit pay plan effect exchange rate project benefit obligation end year change plan asset plan asset fair value begin year actual return plan asset company contribution plan participant contribution settlement divestiture acquisition benefit pay plan asset effect exchange rate plan asset fair value end year fund status end year amount recognize company balance sheet consist follow noncurrent asset current liability noncurrent liability total recognize consolidated balance sheet end year amount recognize accumulate comprehensive income consist follow net actuarial loss gain prior service cost credit unrecognized net transition asset total tax effect accumulate benefit obligation end year change plan asset benefit obligation recognize comprehensive income net periodic benefit cost net actuarial loss gain amortization net actuarial loss prior service cost amortization prior service cost effect exchange rate total recognize comprehensive income tax total recognize net periodic benefit cost comprehensive income plan accumulate benefit obligation excess plan asset consist follow retirement plan dollar million accumulate benefit obligation project benefit obligation plan asset fair value johnson johnson annual reportstrategic asset allocation determine country base nature liability consider demographic composition plan participant average age year service active versus retiree status company plan consider nonmature plan longterm strategic asset allocation consistent type plan emphasis place diversify equity broad basis combine currency match fix income asset follow table display project future benefit payment companys retirement benefit plan dollar million project future benefit payment retirement plan benefit plan gross medicare rebate benefit plan net company require fund retirement plan require anticipate funding meet minimum statutory funding requirement international plan fund accordance local regulation additional discretionary contribution deem appropriate meet longterm obligation plan certain country united states fund pension plan common practice funding provide economic benefit consequently company pension plan fund follow table display project future minimum contribution company international unfunded retirement plan amount include discretionary contribution company elect future dollar million project future contribution unfunde retirement plan unfunde international retirement plan company retirement plan asset allocation end target allocation follow percent target plan asset allocation retirement plan equity security debt security total plan asset international retirement plan equity security debt security real estate total plan asset company benefit plan unfunded life insurance contract asset million million december december respectively fair value johnson johnson common stock directly hold plan asset million total plan asset december million total plan asset december note consolidated financial statement cash cash equivalent marketable security december december amortize unrealized estimate amortize unrealized estimate dollar million cost gainslosse fair value cost gainslosse fair value current investment cash government security obligation corporate debt security money market fund time deposit total cash cash equivalent current marketable security noncurrent investment marketable security financial instrument company follow provision sfas require derivative instrument record balance sheet fair value december balance defer net loss derivative include accumulate comprehensive income million aftertax additional information note company expect substantially reclassify earning month result transaction expect occur period maximum length time company hedge transaction exposure month ultimately realize earning differ foreign exchange rate change realize gain loss ultimately determine actual exchange rate maturity derivative derivative gainslosse initially report component comprehensive income reclassify earning period forecast transaction affect earning year end december december january net impact hedge ineffectiveness transaction qualify hedge accounting discontinuance hedge company financial statement insignificant refer note disclosure movement accumulate comprehensive income concentration credit risk company invest excess cash deposit major bank world highquality money market instrument company policy make investment commercial institution equivalent credit rating average investment mature month company incur relate loss saving plan company voluntary k saving plan design enhance exist retirement program cover eligible employee company match percentage employee contribution consistent provision plan heshe eligible total company match contribution plan million million million merger acquisition divestiture certain business acquire million cash million liability assume acquisition account purchase method accordingly result operation include financial statement respective date acquisition acquisition include conor medsystem inc cardiovascular device company new drug delivery technology robert reid inc japanese orthopedic product distributor mayas mom inc social medium company excess purchase price estimate fair value tangible asset acquire amount million assign identifiable intangible asset residual record goodwill approximately million identify value iprd associate acquisition conor medsystems inc iprd charge relate acquisition conor medsystems inc million associate research relate discovery application stent technology value iprd calculate cash flow projection discount risk inherent project discount rate apply certain business acquire billion cash billion liability assume acquisition account purchase method accordingly result operation include financial statement respective date acquisition note december company complete acquisition consumer healthcare business pfizer inc purchase price billion cash operating result consumer healthcare business pfizer inc report company financial statement begin result subsequent acquisition date significant order obtain regulatory approval transaction company agree divest certain overlapping business company complete divestiture zantac product december divestiture kaopectate unisom cortizone balmex act product january follow table provide pro forma result operation fiscal year end january fiscal year end december consumer healthcare business pfizer inc acquire begin johnson johnson annual reportperiod present pro forma result include effect divestiture certain purchase accounting adjustment estimate change depreciation amortization expense acquire tangible intangible asset pro forma result include anticipate cost saving effect plan integration consumer healthcare business pfizer inc accordingly amount necessarily indicative result acquisition occur date indicate occur future unaudited pro forma result year end year end december january dollar million share datum net sale net earning dilute net earning share company complete allocation purchase price individual asset acquire liability assume follow table present complete allocation purchase price consumer healthcare business pfizer inc date acquisition dollar million current asset property plant equipment defer tax asset goodwill intangible asset total asset acquire current liability noncurrent liability total liability assume net asset acquire acquisition consumer healthcare business pfizer inc result billion goodwill allocate consumer segment purchase price allocation identifiable intangible asset effect amortization include current period balance sheet follow dollar million intangible asset determinable life brand patent technology customer relationship total amortizable intangible brand indefinite live total intangible asset weight average life million total amortizable intangible approximately year date acquisition majority intangible asset valuation relate brand assessment brand indefinite life determinable life base number factor include competitive environment market share brand history product life cycle operating plan macroeconomic environment country brand sell brand account total value indefinitelife brand include listerine nicorette neosporin sudafe benadryl visine benylin determinablelife brand include purell actife efferdent regional country specific brand determinablelife brand asset live range year patent technology intangible concentrate upper respiratory oral care medicate skin care tobacco dependence hair growth business asset live range year estimate customer relationship intangible asset useful life range year reflect low historical project customer attrition rate consumer healthcare business pfizer inc major retailer distributor customer iprd charge relate acquisition consumer healthcare business pfizer inc million pretax basis million aftertax basis primarily associate right obtain switch zyrtec prescription overthecounter status switch approve fda effective november value iprd calculate cash flow projection discount risk inherent project probability success factor reflect inherent regulatory risk acquisition date discount rate apply company complete analysis integration plan pursuant company incur cost primarily relate elimination certain duplicate sell general administrative function company area global business service corporate staff gotomarket support excess manufacturing capacity addition acquisition consumer healthcare business pfizer inc acquisition include animas corporation lead maker insulin infusion pump related product hand innovation llc privately hold manufacturer fracture fixation product upper extremity future medical system sa privately hold company primarily develop manufacture market arthroscopic fluid management system vascular control systems inc privately hold company focus develop medical device treat fibroid control bleed obstetric gynecologic application group vendme sa privately hold french marketer adult baby skin care product colbar lifescience ltd privately hold company specialize reconstructive medicine tissue engineering ensure medical inc privately hold company develop device postcatheterization closure femoral artery exclude acquisition consumer healthcare business pfizer inc excess purchase price estimate fair value tangible asset acquire amount million assign identifiable intangible asset residual record goodwill approximately million identify value iprd primarily associate acquisition hand innovation llc future medical system sa vascular control systems inc colbar lifescience ltd ensure medical inc iprd charge relate acquisition hand innovation llc million associate fracture note consolidated financial statement repair technology value iprd calculate cash flow projection discount risk inherent project probability success factor range reflect inherent clinical regulatory risk discount rate apply iprd charge relate acquisition future medical system sa million associate nextra duo pump product technology value iprd calculate cash flow projection discount risk inherent project probability success factor technology reflect inherent clinical regulatory risk discount rate apply iprd charge relate acquisition vascular control systems inc million associate flostat system technology value iprd calculate cash flow projection discount risk inherent project probability success factor reflect inherent clinical regulatory risk discount rate apply iprd charge relate acquisition colbar lifescience ltd million associate evolence family product biodegradable dermal filler value iprd calculate cash flow projection discount risk inherent project probability success factor range reflect inherent clinical regulatory risk discount rate apply iprd charge relate acquisition ensure medical inc million associate femoral artery closure device value iprd calculate cash flow projection discount risk inherent project probability success factor reflect inherent clinical regulatory risk discount rate apply certain business acquire million cash million liability assume acquisition account purchase method accordingly result operation include financial statement respective date acquisition acquisition include transform pharmaceuticals inc company specialize discovery superior formulation novel crystalline form drug molecule closure medical corporation company expertise intellectual property biosurgical market peninsula pharmaceuticals inc biopharmaceutical company focus develop commercialize antibiotic treat lifethreatening infection right consumer professionally dispense rembrandt brand oral care product whiten toothpaste strip system mouth rinse excess purchase price estimate fair value tangible asset acquire amount million assign identifiable intangible asset residual record goodwill approximately million identify value iprd primarily associate acquisition transform pharmaceuticals inc closure medical corporation peninsula pharmaceuticals inc iprd charge relate acquisition transform pharmaceuticals inc million associate research relate discovery application superior formulation value iprd calculate cash flow projection discount risk inherent project discount rate apply iprd charge relate acquisition closure medical corporation million associate omnex surgical sealant vascular indication outside europe potential indication worldwide value iprd calculate cash flow projection discount risk inherent project probability success factor vascular indication indication reflect inherent clinical regulatory risk discount rate apply vascular indication iprd charge relate acquisition peninsula pharmaceuticals inc million associate development doripenem phase iii clinical trial value iprd calculate cash flow projection discount risk inherent project probability success factor reflect inherent clinical regulatory risk discount rate apply remain million iprd associate acquisition international commercial right certain patent knowhow field sedation analgesia scott lab inc value iprd calculate cash flow projection discount risk inherent project discount rate exception consumer health care business pfizer inc supplemental pro forma information sfas business combination sfas goodwill intangible asset provide impact aforementione acquisition material effect company result operation cash flow financial position divestiture material effect company result operation cash flow financial position legal proceeding product liability company involve numerous product liability case unite states concern adverse reaction drug medical device damage claim substantial company confident adequacy warning instruction use accompany product feasible predict ultimate outcome litigation company believe liability result case substantially cover exist amount accrue company balance sheet available thirdparty product liability insurance johnson johnson annual reportmultiple product johnson johnson subsidiary subject numerous product liability claim lawsuit include ortho evra risperdal duragesic charit artificial disc approximately claimant file lawsuit claim injury allegedly ortho evra claimant respect risperdal respect charit respect duragesic claimant seek substantial compensatory available punitive damage respect risperdal attorney general state office general counsel commonwealth pennsylvania file action seek reimbursement medicaid public fund risperdal prescription write offlabel use compensation treat citizen allege adverse reaction risperdal civil fine penalty punitive damage relief attorney general texas join qui tam action state seek similar relief certain action seek injunctive relief relate promotion risperdal attorney general number state indicate potential interest pursue similar litigation company janssen subsidiary obtain tolling agreement stay run statute limitation inquire issue addition case file union health plan seek damage allege overpayment risperdal seek certification class action numerous claim lawsuit united states relate drug propulsid withdraw general sale company janssen subsidiary resolve currently enrol settlement program aggregate cap million litigation concern propulsid pende canada class action person allege adverse reaction drug certify affirmative stent patent litigation patent infringement action try delaware federal district court late cordis corporation cordis subsidiary johnson johnson obtain verdict infringement patent validity damage awards boston scientific corporation boston scientific medtronic ave inc medtronic base number cordis vascular stent patent december jury damage action boston scientific return verdict million jury medtronic action return verdict million court appeal federal circuit recently uphold liability case return case district court proceeding include damage cordis arbitration claim medtronic accuse medtronic infringement sale stent product introduce medtronic subsequent product subject early action reference subsequent product find license medtronic pursuant license arbitration panel march arbitration proceeding determine royalty owe product january cordis file patent infringement action boston scientific delaware federal district court accuse express taxus liberte stent infringe palmaz patent expire november liberte stent accuse infringe cordis gray patent expire june jury find express taxus liberte stent infringe palmaz patent liberte stent infringe gray patent boston scientific appeal court appeal federal circuit patent litigation johnson johnson subsidiaries product johnson johnson subsidiary subject patent lawsuit outcome potentially adversely affect ability subsidiary sell product require payment past damage future royalty july jury federal district court delaware find cordis cypher stent infringe boston scientific ding patent cordis cypher bx velocity stent infringe boston scientifics jang patent jury find patent valid boston scientific seek substantial damage injunction action district court deny motion cordis overturn jury verdict grant new trial cordis appeal court appeal federal circuit district court indicate consider damage willfulness injunctive relief appeal decide boston scientific bring action belgium netherlands germany france kastenhofer patent purport cover twolayer catheter deliver cypher stent enjoin manufacture sale allegedly infringe catheter country recover damage hear belgian case schedule decision low court netherlands boston scientifics favor reverse appeal april boston scientific file appeal dutch supreme court october boston scientific prevail nullity action challenge validity kastenhofer patent file cordis germany cordis intend appeal hearing schedule french action trial boston scientific case base kastenhofer patent conclude federal court california october jury verdict favor cordis jury find kastenhofer patent invalid find cordis respect infringement patent assert cordis counterclaim post trial motion appeal anticipate germany boston scientific action base ding patent pende cordis cypher stent cordis successful action trial level boston scientific appeal note consolidated financial statement follow chart summarize patent lawsuit concern product johnson johnson subsidiary proceed trial jj plaintiff product company patent patent holder court trial date date file twolayer cordis kasten boston scientific corp multiple european catheter hofer forman contact lense vision care nicolson ciba vision md fl multiple european stents cordis ricci medtronic evysio ed tx cypher stent cordis wall wall ed tx cypher stent cordis bonutti marctec sd il cypher stent cordis saffran saffran ed tx trial date establish litigation filer abbreviate new drug application anda follow chart indicate lawsuit pende generic firm file abbreviate new drug application anda seek market generic form product sell subsidiary company prior expiration applicable patent cover product anda typically include allegation noninfringement invalidity unenforceability patent event subsidiary company involve successful action statutory month stay expire rule district court obtain firm involve ability fda approval introduce generic version product issue result substantial market share revenue loss product company subsidiary note follow chart month stay expire expire respect anda challenge product brand patentnda generic trial date month product holder challenger court date file stay expiration aciphex eisai teva dr reddys sd ny mg delay janssen sd ny release tablet concerta mcneilppc andrx de mg alza controlled release tablet levaquin orthomcneil lupin nj mg tablets ortho tri cyclen lo orthomcneil barr nj mg mg mg mg mg mg pepcid complete mcneilppc perrigo sd ny razadyne janssen teva de mylan de dr reddys de purepac de barr de par de alphapharm de razadyne er janssen barr nj sandoz nj kv pharma nj johnson johnson annual reportbrand patentnda generic trial date month product holder challenger court date file stay expiration risperdal oral janssen apotex nj solution mgml topamax orthomcneil mylan nj mg tablet cobalt nj topamax sprinkle orthomcneil cobalt nj mg capsule mylan nj ultracet orthomcneil apotex nd il ultram er orthomcneil par de mg tablet trial date establish trial action teva dr reddys mylan respect anda challenge patent aciphex eisai inc companys subsidiary orthomcneil pharmaceutical inc orthomcneil marketing partner proceed district court new york march court hold aciphex compound patent enforceable court previously hold patent valid teva dr reddys appeal decision court appeal federal circuit mylan withdraw appeal action apotex risperdal risperidone oral solution trial court dismiss apotexs challenge validity infringement patent relate formulation oral solution product apotex appeal decision october action mylan respect patent topamax district court new jersey grant motion orthomcneil preliminary injunction bar launch mylan generic versions topamax february district court grant orthomcneil motion summary judgment dismiss mylan claim patent obvious remain issue case court enter judgment case orthomcneil enter injunction prohibit mylan marketing generic topiramate product date early patent expiration september mylan appeal rule april district court enter judgment cobalt pursuant stipulation bind outcome mylan suit cobalt appeal rule court appeal hear argument appeal november ruling expect near term action perrigo patent pepcid complete district court southern district new york june hold patent invalid obvious company subsidiary mcneilppc inc appeal decision partner merck co inc johnson johnsonmerck consumer pharmaceutical co action barr alphapharm respect anda challenge razadyne patent janssen licenses synaptech inc fourday nonjury trial hold district court delaware court issue rule action action andrx respect anda challenge concerta patents fiveday nonjury trial hold district court delaware december court issue rule action action sandoz respect anda challenge razadyne er patent janssen licenses synaptech inc action stay pende outcome litigation delaware federal court sandoz challenge patent razadyne er certify await expiration second patent marketing generic version razadyne er action teva respect anda challenge axert patent janssen licenses almirall prodesfarma sa party settle dispute court enter consent judgment january week follow adverse rule ditropan xl anda litigation mylan september johnson johnson alza receive seven antitrust class action complaint file purchaser product allege johnson johnson alza violate federal state antitrust law knowingly pursue baseless patent litigation delay entry market mylan impax late plaintiff case dismiss claim prejudice average wholesale price awp litigation johnson johnson pharmaceutical subsidiary numerous pharmaceutical company defendant series lawsuit state federal court involve allegation pricing market certain pharmaceutical product amount fraudulent actionable conduct thing company allegedly report inflated average wholesale price awp drug issue case federal action state action remove federal court consolidated pretrial purpose multidistrict litigation mdl federal district court boston massachusetts plaintiffs case include class private person entity pay portion purchase drug issue base awp state government entity medicaid payment drug issue base awp mdl court identify class massachusettsonly private insurer provide medigap insurance coverage private payer physicianadministere drug payment base awp class class national class individual copayment physicianadministere drug cover medicare class trial massachusettsonly class action conclude mdl court december june mdl court issue posttrial ruling dismiss johnson johnson defendant case claim class subsequently class trial action bring note consolidated financial statement attorney general state alabama make allegation relate awp expect proceed additional awp case bring attorney general expect set trial july centocor inc johnson johnson subsidiary receive request voluntarily provide document information criminal division attorney office district new jersey connection investigation centocor marketing practice subsequent request document receive attorney office company centocor respond process respond request document information december orthomcneil receive subpoena attorney office boston massachusetts seek document relate marketing include alleged offlabel marketing drug topamax topiramate additional subpoena document receive orthomcneil cooperating respond subpoena october attorney office boston ask attorney orthomcneil cooperate facilitating subpoena testimony present orthomcneil employee federal grand jury boston cooperation secure testimony additional witness grand jury request provide january janssen receive subpoena office inspector general office personnel management seek document concern sale marketing payment physician connection sale marketing clinical trial risperdal risperidone document subsequent request additional subpoena seek information marketing adverse reaction risperdal receive attorney office eastern district pennsylvania november subpoenas seek testimony witness grand jury receive janssen cooperate respond subpoena august johnson johnson health care systems inc hcs johnson johnson subsidiary receive subpoena dallas texas attorney office seek document relate relationship group purchasing organization novation hcs johnson johnson subsidiary company subsidiary involve respond subpoena september ortho biotech inc ortho biotech receive subpoena office inspector general denver colorado field office seek document direct sale marketing procrit epoetin alfa present dealing oncology inc healthcare service network oncologist ortho biotech respond subpoena september plaintiff employment discrimination litigation initiate company federal district court new jersey move certify class african american hispanic salaried employee company affiliate employ time november present plaintiff seek monetary damage period present include punitive damage equitable relief court deny plaintiff class certification motion december motion reconsideration april plaintiff seek appeal decision march depuy orthopaedics inc depuy johnson johnson subsidiary receive subpoena attorney office district new jersey seek record concern contractual relationship depuy surgeon surgeonsintraine involve hip knee replacement reconstructive surgery investigation resolve depuy lead supplier hip knee implant late september agreement attorney office district new jersey settlement include month defer prosecution agreement dpa acceptance company monitor assure compliance dpa respect company payment settlement monie entry year corporate integrity agreement depuy pay million settlement november attorney general commonwealth massachusetts issue civil investigative demand depuy seek information financial relationship number massachusettsbase orthopedic surgeon provider depuy relationship publicly disclose depuy pursuant dpa february depuy receive write request information united states senate special committee age followup early inquiry concern number aspect dpa depuy respond request june senate committee finance request company produce information use pharmaceutical subsidiary educational grant similar request send major pharmaceutical company july committee specifically request information educational grant connection drug propulsid follow request receive committee additional information january october letter receive senate committee finance request information concern payment list physician specification payment continue medical education honoraria research support etc july scios inc scios johnson johnson subsidiary receive subpoena attorney office district massachusetts seek document relate sale marketing natrecor scio respond subpoena early august scio advise investigation handle attorney office northern district california san francisco september johnson johnson receive subpoena attorney office district massachusetts seek document relate sale marketing drug omnicare inc manager pharmaceutical benefit longterm care facilities johnson johnson subsidiary involve respond subpoena employee company pharmaceutical subsidiary subpoenaed testify grand jury connection investigation november amgen file suit hoffmannlaroche inc district court district massachusetts seek declaration roche product cera roche indicate seek introduce johnson johnson annual reportthe united states infringe number amgen patent concern epo amgen license epo sale united states ortho biotech nondialysis indication trial action conclude october verdict amgen favor roche expect appeal late december early purport class action file behalf purchaser endomechanical instrument company whollyowne subsidiary ethicon inc ethicon endosurgery inc johnson johnson health care systems inc challenge suture endomechanical contract group purchasing organization hospital discount predicate hospital achieving specify market share target category product action file federal district court central district california february johnson johnson receive subpoena securities exchange commission sec request document relate participation johnson johnson subsidiaries united nations iraq oil food program subsidiary cooperate sec department justice doj produce responsive document june depuy receive subpoena dojs antitrust division request document relate manufacture marketing sale orthopaedic device search warrant execute connection investigation depuy respond request document wake publicity subpoena depuy serve civil antitrust class action case dismiss prejudice right file future september janssen receive subpoena attorney general state california seek document sale marketing sideeffect risperdal interaction state official state formulary medicaidreimburse drug janssen respond subpoena november centocor receive subpoena seek document connection investigation conduct office united states attorney central district california centocor average selling price asp calculation remicade company contract purchase program centocor produce material responsive subpoena centocor advise investigation closed february johnson johnson voluntarily disclose doj sec subsidiary outside united states believe improper payment connection sale medical device smallmarket country payment fall jurisdiction foreign corrupt practice act fcpa course continue dialogue agency issue potentially rise level fcpa violation additional market bring attention agency company company provide continue provide additional information doj sec cooperate agency review matter march cordis receive letter request document committee oversight government reform house representative marketing safety drugeluting stent cordis cooperate respond request march company receive separate subpoena attorney office philadelphia attorney office boston attorney office san francisco subpoenas relate investigation office reference concern respectively sale marketing risperdal janssen topamax orthomcneil natrecor scios subpoena request information company corporate supervision oversight subsidiary include sale marketing drug company cooperate respond request addition attorney office boston issue subpoenas employee johnson johnson march company receive letter committee energy commerce house representative seek answer question marketing safety procrit erythropoietin product sell orthobiotech senator grassley ranking member united states senate committee finance send company letter seek information relate procrit company provide initial response july new york state attorney general issue subpoena seek information relate procrit like house senate request subpoena ask material relate procrit safety marketing pricing company respond request april company receive subpoena office attorney general state delaware subpoena seek document information relate nominal pricing agreement purpose subpoenas nominal pricing agreement define agreement company agree provide pharmaceutical product percent average manufacturer price product company respond subpoena cooperate inquiry august company receive request document interview witness committee energy commerce house representative concern gmp good manufacturing practice issue involve cypher stent letter state fda inspector identify numerous systemic violation gmp connection cypher manufacturing nonetheless allow cordis continue market cypher stent cordis cooperate respond request october company receive request document senator grassley behalf committee finance senate concern continue medical education payment specific physician company process comply request december company subsidiary janssen receive request senator grassley behalf committee finance senate document information concern marketing promotion risperdal use nursing home patient company process collect responsive document obtain relevant information respect matter company subsidiary vigorously contest allegation assert pursue defense maximize prospect success company subsidiary involve matter continually evaluate strategy manage matter appropriate pursue settlement note consolidated financial statement resolution good interest company company involve number patent trademark lawsuit incidental business ultimate legal financial liability company respect claim lawsuit proceeding refer estimate certainty company opinion base examination matter experience date discussion counsel ultimate outcome legal proceeding net liability accrue company balance sheet expect material adverse effect company financial position resolution report period matter significant impact company result operation cash flow period earning share follow reconciliation basic net earning share dilute net earning share fiscal year end december december january share million share datum basic net earning share average share outstanding basic potential share exercisable stock option plan share repurchase treasury stock method convertible debt share adjust average share outstanding diluted diluted net earning share dilute net earning share calculation include dilutive effect convertible debt decrease interest expense million million million tax year respectively diluted net earning share exclude million million million share underlie stock option respectively exercise price option great average market value result antidilutive effect dilute earning share capital treasury stock change treasury stock amount million treasury stock treasury stock number share thousand share balance january employee compensation stock option plan conversion subordinate debenture repurchase common stock balance january employee compensation stock option plan conversion subordinate debenture repurchase common stock balance december employee compensation stock option plan conversion subordinate debenture repurchase common stock balance december aggregate share common stock issue approximately million share end cash dividend pay share compare dividend share share johnson johnson annual report select quarterly financial datum unaudite select unaudited quarterly financial datum year summarize second fourth second fourth dollar million share datum quarter quarter quarter quarter quarter quarter quarter quarter segment sale customer consumer pharmaceutical med device diagnostic total sale gross profit earning provision taxis income net earning basic net earning share dilute net earning share quarter include aftertax charge million iprd quarter include aftertax charge million restructuring fourth quarter include aftertax charge million natrecor intangible asset writedown onetime tax gain million restructure low tax rate increase taxable income low tax jurisdiction relative taxable income high tax jurisdiction quarter include aftertax gain million guidant acquisition termination fee aftertax charge million iprd second quarter include aftertax charge million iprd quarter include aftertax charge million iprd fourth quarter include aftertax charge million iprd restructuring quarter company announce restructuring initiative effort improve overall cost structure action take offset anticipate negative impact associate generic competition pharmaceutical segment challenge drugelute stent market company pharmaceutical segment reduce cost base consolidate certain operation continue invest recently launch product latestage pipeline new product cordis franchise move integrate business model address market change underway drugeluting stent well serve broad spectrum patient cardiovascular need reduce cost base program allow company accelerate step standardize streamline certain aspect enterprisewide function human resource finance information technology support growth business leverage scale effectively area procurement benefit operate company additionally program company plan eliminate approximately position approximately eliminate fiscal quarter company record million relate pretax charge approximately million pretax restructuring charge expect require cash payment million restructuring charge consist severance cost million asset writeoff million million relate leasehold obligation million asset writeoff relate property plant equipment million intangible asset million asset million follow table summarize severance charge associate spend fiscal year end dollar million severance severance charge cash outlay reserve balance december cash outlay severance expect pay month accordance company plan local law additional information restructuring relate segment note note consolidated financial statement management report internal control financial reporting section sarbanesoxley act management require assess effectiveness company internal control financial reporting end fiscal year report base assessment company internal control financial report effective management company responsible establish maintain adequate internal control financial reporting company internal control financial reporting design provide reasonable assurance reliability company financial reporting preparation financial statement accordance generally accept accounting principle internal control financial reporting matter design inherent limitation internal control financial reporting determine effective provide reasonable assurance respect financial statement preparation prevent detect misstatement projection evaluation effectiveness future period subject risk control inadequate change condition degree compliance policy procedure deteriorate company management assess effectiveness company internal control financial reporting december make assessment company criterion establish committee sponsor organization treadway commission coso internal controlintegrate framework criterion area control environment risk assessment control activity information communication monitoring company assessment include extensive documenting evaluating testing design operating effectiveness internal control financial reporting base company process assessment describe management conclude december company internal control financial report effective effectiveness company internal control financial reporting december audit pricewaterhousecooper llp independent register public accounting firm state report appear william c weldon dominic j caruso william c weldon dominic j caruso chairman board vice president finance director chief chief financial officer executive officer johnson johnson annual reportreport independent register public accounting firm shareholder board directors johnson johnson opinion accompany consolidated balance sheet relate consolidated statement earning statement equity statement cash flow present fairly material respect financial position johnson johnson subsidiaries company december december result operation cash flow year period end december conformity accounting principle generally accept united states america opinion company maintain material respect effective internal control financial reporting december base criterion establish internal control integrate framework issue committee sponsor organization treadway commission coso company management responsible financial statement maintain effective internal control financial reporting assessment effectiveness internal control financial reporting include accompany management report internal control financial reporting responsibility express opinion financial statement companys internal control financial reporting base integrated audits conduct audits accordance standard public company accounting oversight board united states standard require plan perform audits obtain reasonable assurance financial statement free material misstatement effective internal control financial reporting maintain material respect audits financial statement include examine test basis evidence support amount disclosure financial statement assess accounting principle significant estimate management evaluate overall financial statement presentation audit internal control financial reporting include obtain understand internal control financial reporting assess risk material weakness exist test evaluate design operating effectiveness internal control base assess risk audits include perform procedure consider necessary circumstance believe audits provide reasonable basis opinion company internal control financial reporting process design provide reasonable assurance reliability financial reporting preparation financial statement external purpose accordance generally accept accounting principle companys internal control financial reporting include policy procedure pertain maintenance record reasonable detail accurately fairly reflect transaction disposition assets company ii provide reasonable assurance transaction record necessary permit preparation financial statement accordance generally accept accounting principle receipt expenditure company accordance authorization management director company iii provide reasonable assurance prevention timely detection unauthorized acquisition use disposition company asset material effect financial statement inherent limitation internal control financial reporting prevent detect misstatement projection evaluation effectiveness future period subject risk control inadequate change condition degree compliance policy procedure deteriorate pricewaterhousecooper llp new york new york february report independent register public accounting firm summary operation statistical data dollar million share figure sale customer sale customer international total sale cost product sell sell marketing administrative expense research expense purchase inprocess research development interest income interest expense net portion capitalize income expense net restructure earning provision taxis income provision taxis income net earning percent sale customer dilute net earning share common stock percent return average shareholder equity percent increase previous year sale customer dilute net earning share supplementary expense datum cost material service total employment cost depreciation amortization maintenance repair total tax expense supplementary balance sheet datum property plant equipment net addition property plant equipment total asset longterm debt operate cash flow common stock information dividend pay share shareholder equity share market price share yearend close average share outstanding million basic diluted employee thousand net interest income include cost material service category include taxis income payroll property business taxis include million tax writedown relate natrecor intangible asset summary operation statistical datashareholder return performance graph set forth line graph compare cumulative total shareholder return company common stock period year year end december cumulative total return standard poor stock index standard poors pharmaceutical index standard poors health care equipment index graph table assume invest december december company common stock standard poor stock index standard poors pharmaceutical index standard poors health care equipment index dividend reinveste performance graph johnson johnson sp index sp pharmaceutical index sp health care equipment index performance graph johnson johnson sp index sp pharmaceutical index sp health care equipment index shareholder return performance graph ex yexvhtm ex subsidiary exhibit subsidiary johnson johnson new jersey corporation domestic international subsidiary show december certain subsidiary international subsidiary name significant aggregate johnson johnson parent jurisdiction subsidiary organization subsidiarie advanced sterilization product services inc new jersey alza corporation delaware alza land management inc delaware animas corporation delaware biosense webster inc california centocor biologics llc pennsylvania centocor inc pennsylvania centocor ortho biotech services llc new jersey centocor research development inc pennsylvania closure medical corporation delaware cna development llc delaware codman shurtleff inc new jersey conor medsystems llc delaware cordis corporation florida cordis development corporation florida cordis international corporation delaware cordis llc delaware cordis neurovascular inc florida crescendo pharmaceuticals corporation delaware depuy inc delaware depuy mitek inc massachusetts depuy orthopaedics inc indiana depuy products inc indiana depuy spine inc ohio depuy spine sales limited partnership massachusetts diabetes diagnostic inc delawareethicon endosurgery inc ohio ethicon endosurgery llc delaware ethicon endosurgery services lp texas ethicon inc new jersey ethicon llc delaware global biologics supply chain llc pennsylvania guh corporation delaware gynopharma inc delaware hand innovation llc delaware innovational holdings llc delaware iso holding corp delaware jj holdings nevada inc nevada janssen ortho llc delaware jjhc llc delawarejurisdiction subsidiary organization johnson johnson baby products inc delaware johnson johnson consumer company inc new jersey johnson johnson development corporation new jersey johnson johnson finance corporation new jersey johnson johnson health care systems inc new jersey johnson johnson international new jersey johnson johnson japan inc new jersey johnson johnson merck consumer pharmaceutical co new jersey johnson johnson middle east inc new jersey johnson johnson pharmaceutical research development llc new jersey johnson johnson pharmaceutical services llc new jersey johnson johnson pharmaceutical trading co inc delaware johnson johnson professional co pr inc delaware johnson johnson regenerative therapeutics llc delaware johnson johnson sales logistics company llc new jersey johnson johnson services inc new jersey johnson johnson urban renewal associates new jersey johnson johnson vision care inc florida joint medical product corporation delaware lifescan inc california lifescan llc delaware lifescan products llc delaware mcneil consumer healthcare latin america llc delaware mcneil healthcare llc delaware mcneil nutritionals llc delaware mcneilppc inc new jersey middlesex assurance company limited vermont neutrogena corporation delaware nitinol development corporation california noramco inc georgia omj pharmaceuticals inc delaware orapharma inc delaware ortho biologics llc delaware ortho biotech holding corp delaware ortho biotech inc new jersey ortho biotech products lp new jersey orthoclinical diagnostics inc new york orthomcneil finance co florida orthomcneiljanssen pharmaceuticals inc pennsylvania rutan realty llc new jersey scios inc delaware terame corporation delaware therapeutic discovery corporation delaware tylenol company new jersey transform pharmaceuticals inc delaware wv resources inc delawarejurisdiction subsidiary organization international subsidiaries alza ireland limited ireland apsis sas france carlo erba otc srl italy centocor biologics ireland limited ireland centocor bv netherlands cilag advanced technologies gmbh switzerland cilag ag switzerland cilag de mexico de rl de cv mexico cilag gmbh international switzerland cilag holding ag switzerland cilag pharmaceuticals gmbh switzerland codman sarl switzerland colbar lifescience ltd israel cordis cashel limited ireland cordis europa nv netherlands cordis medizinische apparate gmbh germany cordis sas france depuy ace sarl switzerland depuy france sas france depuy international limited united kingdom depuy international holdings limited united kingdom depuy ireland limited ireland depuy mitek sarl switzerland depuy orthopadie gmbh germany depuy orthopedie sas france depuy spine sarl switzerland depuy uk holdings limited united kingdom drumbeat limited united kingdom ees holdings de mexico de r l de c v mexico ees sa de cv mexico ethicon gmbh germany ethicon ireland limited ireland ethicon sarl switzerland ethicon sas france ethicon womens health urology sarl switzerland ethnor del istmo sa panama ethnor farmaceutica sa venezuela ethnor proprietary limited south africa fms future medical system sa switzerland gme health care limited ireland group vendme sas france high wycombe property management limit united kingdom janssencilag ab sweden janssencilag denmark janssencilag ag switzerland janssencilag bv netherlands janssencilag farmaceutica lda portugaljurisdiction subsidiary organization janssencilag farmaceutica ltda brazil janssencilag gmbh germany janssencilag ltd thailand janssencilag limited united kingdom janssencilag nv belgium janssencilag oy finland janssencilag pharmaceutical saci greece janssencilag pharma gmbh austria janssencilag polska sp z oo poland janssencilag pty ltd australia janssencilag sa spain janssencilag sa de cv mexico janssencilag sas france janssencilag spa italy janssen korea ltd korea janssenortho inc canada janssen pharmaceutica nv belgium janssen pharmaceutica pty limited south africa janssen pharmaceutical kk japan janssen pharmaceutical limited ireland jc general services cvba belgium jc healthcare ltd israel jhc nederland bv netherlands johnson johnson ab sweden johnson johnson ag switzerland johnson johnson china investment co ltd china johnson johnson china ltd china johnson johnson consumer france sas france johnson johnson consumer hong kong limited hong kong johnson johnson de argentina sace argentina johnson johnson de colombia sa colombia johnson johnson de mexico sa de cv mexico johnson johnson de venezuela sa venezuela johnson johnson del peru sa peru johnson johnson brasil industria e comercio de produtos para saude ltda brazil johnson johnson european treasury company ireland johnson johnson egypt sae egypt johnson johnson finance limited united kingdom johnson johnson financial services gmbh germany johnson johnson gesellschaft mbh austria johnson johnson gmbh germany johnson johnson group holdings gmbh germany johnson johnson hellas sa greece johnson johnson hemisferica sa puerto rico johnson johnson holding ab sweden johnson johnson holding gmbh germany johnson johnson hong kong limited hong kong johnson johnson inc canadajurisdiction subsidiary organization johnson johnson industrial ltda brazil johnson johnson international financial services company ireland johnson johnson kft hungary johnson johnson k k japan johnson johnson korea ltd korea johnson johnson limitada portugal johnson johnson limited india johnson johnson llc russia johnson johnson luxembourg finance company sarl luxembourg johnson johnson management limited united kingdom johnson johnson medical bv netherlands johnson johnson medical china ltd china johnson johnson medical holding spa italy johnson johnson medical korea limited korea johnson johnson medical limited united kingdom johnson johnson medical mexico sa de cv mexico johnson johnson medical nv belgium johnson johnson medical products gmbh austria johnson johnson medical pty limited south africa johnson johnson medical pty ltd australia johnson johnson medical shanghai ltd china johnson johnson medical spa italy johnson johnson medical suzhou ltd china johnson johnson pacific pty limited australia johnson johnson pakistan private limited pakistan johnson johnson philippines inc philippines johnson johnson poland sp z oo poland johnson johnson proprietary limited south africa johnson johnson pte ltd singapore johnson johnson pty limited australia johnson johnson sa spain johnson johnson sdn bhd malaysia johnson johnson spa italy johnson johnson sro czech republic johnson johnson sro slovakia johnson johnson swiss finance company limited united kingdom johnson johnson taiwan ltd taiwan johnson johnson thailand ltd thailand johnson johnson vision care ireland limited ireland johnson johnson vision care shanghai ltd china laboratoire polive snc france laboratoire vendome sas france latam international investment company ireland latam property holdings ireland lifescan canada ltd canada lifescan scotland limited united kingdom mcneil ab sweden mcneil comm va belgiumjurisdiction subsidiary organization mcneil consumer healthcare gmbh germany mcneil denmark aps denmark mcneil esbjerg aps denmark mcneil gmbh co ohg germany mcneil healthcare uk limited united kingdom mcneil iberica slu spain mcneil pdi inc canada mcneil products limited united kingdom mcneil sante grand public france mcneil sweden ab sweden medos international sarl switzerland medos sarl switzerland obtech medical sarl switzerland omj ireland limited ireland omj manufacturing limited ireland orthoclinical diagnostic united kingdom orthoclinical diagnostic gmbh germany orthoclinical diagnostic kk japan orthoclinical diagnostic nv belgium orthoclinical diagnostic sas france pfizer consumer healthcare mexico de rl de cv mexico pfizer consumer healthcare scompa spain pfizer consumer healthcare srl italy pt johnson johnson indonesia indonesia shanghai johnson johnson pharmaceuticals ltd china tasmanian alkaloid pty ltd australia tibotec pharmaceutical limited ireland tibotecvirco comm va belgium tibotecvirco virology bvba belgium turnbuckle investment company ireland vania expansion snc france xianjanssen pharmaceutical ltd china recently acquire change pende ex yexvhtm ex consent pricewaterhousecooper llp exhibit consent independent register public accounting firm consent incorporation reference registration statement form form johnson johnson report date february relate financial statement effectiveness internal control financial reporting appear annual report shareholder incorporate annual report consent incorporation reference report date february relate financial statement schedule appear pricewaterhousecooper llp pricewaterhousecooper llp new york new york february exa yexvwahtm exa certification exhibit acertification chief executive officer pursuant section sarbanesoxley act william c weldon certify review annual report fiscal year end december report johnson johnson company base knowledge report contain untrue statement material fact omit state material fact necessary statement light circumstance statement misleading respect period cover report base knowledge financial statement financial information include report fairly present material respect financial condition result operation cash flow company period present report company certify officer responsible establish maintain disclosure control procedure define exchange act rule ae de internal control financial reporting define exchange act rules af df company design disclosure control procedure cause disclosure control procedure design supervision ensure material information relate company include consolidated subsidiary known entity particularly period report prepare b design internal control financial reporting cause internal control financial reporting design supervision provide reasonable assurance reliability financial reporting preparation financial statement external purpose accordance generally accept accounting principle c evaluated effectiveness company disclosure control procedure present report conclusion effectiveness disclosure control procedure end period cover report base evaluation disclose report change company internal control financial reporting occur company recent fiscal quarter company fourth fiscal quarter case annual report materially affect reasonably likely materially affect company internal control financial reporting company certify officer disclose base recent evaluation internal control financial reporting company auditor audit committee company board director person perform equivalent function significant deficiency material weakness design operation internal control financial reporting reasonably likely adversely affect company ability record process summarize report financial information b fraud material involve management employee significant role company internal control financial reporting william c weldon william c weldon chief executive officer date february exb yexvwbhtm exb certification exhibit b certification chief financial officer pursuant section sarbanesoxley act dominic j caruso certify review annual report fiscal year end december report johnson johnson company base knowledge report contain untrue statement material fact omit state material fact necessary statement light circumstance statement misleading respect period cover report base knowledge financial statement financial information include report fairly present material respect financial condition result operation cash flow company period present report company certify officer responsible establish maintain disclosure control procedure define exchange act rule ae de internal control financial reporting define exchange act rules af df company design disclosure control procedure cause disclosure control procedure design supervision ensure material information relate company include consolidated subsidiary known entity particularly period report prepare b design internal control financial reporting cause internal control financial reporting design supervision provide reasonable assurance reliability financial reporting preparation financial statement external purpose accordance generally accept accounting principle c evaluated effectiveness company disclosure control procedure present report conclusion effectiveness disclosure control procedure end period cover report base evaluation andd disclose report change company internal control financial reporting occur company recent fiscal quarter company fourth fiscal quarter case annual report materially affect reasonably likely materially affect company internal control financial reporting company certify officer disclose base recent evaluation internal control financial reporting company auditor audit committee company board director person perform equivalent function significant deficiency material weakness design operation internal control financial reporting reasonably likely adversely affect company ability record process summarize report financial information b fraud material involve management employee significant role company internal control financial reporting dominic j caruso dominic j caruso chief financial officer date february exa yexvwahtm exa certification exhibit certification chief executive officer pursuant section sarbanesoxley act undersign william c weldon chief executive officer johnson johnson new jersey corporation company pursuant usc adopt pursuant section sarbanesoxley act certifie good knowledge company annual report fiscal year end december report fully complie requirement section securities exchange act information contain report fairly present material respect financial condition result operation company william c weldon william c weldon chief executive officer date february certification furnish sec report pursuant section sarbanesoxley act shall extent require act deem file company purpose section securities exchange act amend subject liability section exb yexvwbhtm exb certification exhibit b certification chief financial officer pursuant section sarbanesoxley act undersign dominic j caruso chief financial officer johnson johnson new jersey corporation company pursuant usc adopt pursuant section sarbanesoxley act certifie good knowledge company annual report fiscal year end december report fully complie requirement section securities exchange act information contain report fairly present material respect financial condition result operation company dominic j caruso dominic j caruso chief financial officerdate february certification furnish sec report pursuant section sarbanesoxley act shall extent require act deem file company purpose section securities exchange act amend subject liability section ex yexvhtm ex cautionary statement exhibit cautionary statement pursuant private security litigation reform act safe harbor forwardlooke statement company time time certain forwardlooking statement publiclyrelease material write oral forwardlooking statement relate strictly historical current fact anticipate result base management plan subject uncertainty forwardlooke statement identify use word plan expect anticipate estimate word similar meaning conjunction thing discussion future operation financial performance company strategy growth product development regulatory approval market position expenditure forwardlooke statement base current expectation future event company guarantee forwardlooke statement accurate company believe reasonable expectation assumption investor realize underlying assumption prove inaccurate unknown risk uncertainty materialize actual result vary materially company expectation projection investor caution place undue reliance forwardlooke statement furthermore company undertake update forwardlooke statement result new information future event development important factor cause company actual result differ company expectation forwardlooke statement follow economic factor include inflation fluctuation interest rate currency exchange rate potential effect fluctuation revenue expense result margin competitive factor include technological advance achieve patent attain competitor new product introduce competitor challenge company patent competitor allegation company product infringe patent party potentially affect company competitive position ability sell product question require payment past damage future royalty particular generic drug firm file abbreviate new drug application seek market generic form company key pharmaceutical product prior expiration applicable patent cover product event company successful defending result lawsuit generic version product issue introduce result substantial market share revenue loss financial distress bankruptcy experience significant customer supplier impair ability case purchase company product pay product previously purchase meet obligation company supply arrangement impact political economic condition terrorist attack part world military action overseas instability financial market result terrorism military action interruption computer communication system include computer virus impair company ability conduct business communicate internally customer health care change country result pricing pressure include continued consolidation health care provider trend manage care health care cost containment shift government primary payer health care expense government law regulation relate sale promotion reimbursement pricing generally government law regulation affect foreign operation include relate security law compliance trade monetary fiscal policy taxis price control regulatory approval new product license patent right possible drug reimportation legislation competition research involve development improvement new exist product process particularly significant result time time product process obsolescencethe development new improved product important company success area business challenge difficulty inherent product development include potential inability successfully continue technological innovation complete clinical trial obtain regulatory approval united states abroad gain maintain market approval product possibility encounter infringement claim competitor respect patent intellectual property right preclude delay commercialization product significant litigation adverse company include product liability claim patent infringement claim antitrust claim health care industry come increase scrutiny government agency state attorney general result investigation prosecution carry risk significant civil criminal penalty include debarment government business product efficacy safety concern base scientific evidence result product withdrawal recall regulatory action fda foreign counterpart decline sale impact business combination include acquisition divestiture internally company externally pharmaceutical medical device health care industry issuance new revise accounting standard american institute certify public accountant financial accounting standard board securities exchange commission public company accounting oversight board foregoing list set forth factor impact company ability achieve result describe forwardlooke statement investor understand possible predict identify factor consider list complete statement potential risk uncertainty company identify factor list permit private security litigation reform act graphic yygif graphic begin yygif sxmuz mckoqkqlfssxajb mbgvamlgkourqpvjakvspxntovyrbjcvcydiefyrgi mahgcuubgts mpqfn mpiqcbjhn tvqxjxls mmcvcjrdeeyarugqksk mnwpyfdedojspuhaeytumcp mzr mqckvlkggorfwlhp cnoapcpp yapkivmhw mrdxupedytjhanrhtzdab mc mqdfgg udjezkpwbrrpawn mpsrwihpnqrahqpotuppdt g mc lkup hxrdt qdlmnr mikb mzgqywuuwqfwhoq mslcsxsovxx mkyzrhpyee mybhhdqbf mydgfdde eelybqypdnhfgfo mgwpcpfobzoiqzxfgozlzmfjiuspmwy mgbgjygsg ygwgpgssqpg fgnygficfciwp mnrhhmshgyptypxe bljif mhxdrehthzgrphmdq meeryzzijhfljvieobyx mjsztfjfzjbjfxgnrflurbcjxxc mhlvdkgxgzysrgjojomohofjhfjf mhcrjdfblcojlsqfmdjmraujijvwchxh maqbfsdqzkuvuvjh rdktd mjkswu g msse mnirlynbnlag mwhfshdhnjpkpipldihenenhdil mqhgnmruucajecavcqrx mcruryo f mnwwpgsewqg tkucoumlueluwuel muxstksprtlubqsetbswtlsu muusulyewwwyi mdzonvngcnkmwomxldjufnn wmreqiqjanncbcdgf mommwfjwpwbwmiql munybuwirysnkorzijngfemncu mcsqnwhnyiceipgrgnwgtfer mxkppnrjmbdsqfsdycsn mcodltmougemegbwofmcccc mznwuiyiiimxandtoyruorso mqsovfloo dkyxywycvy mbicxdacehdcscigxccjfghvrlumkxnj movtjlck mzgjzrxpalkqxcbfszktjzaiwdrsnseyi mgbqxkmuosueahhffptajttuil mgnukohznwn mlppp loqqvztagphjocca xrp mqehdpwvugclm ahfyhcp alluppusbjciqb mup l end graphic yygif graphic begin yygif mteuuokyffekvgywbxneifbdpmgxq mluumzcjahaovynowlzbjtjgkkosyvg mdqgy mznbxnwm mwhvpmzeinnsmuurreor mahupgae meljpxsjtyalcqspexpgqqtgsc mxfhxybogpphxfclnwzhe apiegbcjeofn miyyddfrcb myzelatrydomoipxaie mkwyskistvnbiwh mehpjporrpqhwjaljhbact mpdlqmnpqafswcxlvquvrdprxpj motsnytppbtqudugeq cg mtdznkehnqmgcrftv mtbcmqczm bqihjdcaxitx mjr mneiibslhatdaixfasz mudhl mahkghxthpqtx mwyireznorfvlluxrvncbwyy mekpxnww sfgfqteikfxkejzfqd mvyaimskfcsvbrusvlbentqinbhjkblxlpppoe mxptytmunrwpyaxnbqxafwrttbzemoxkngqzh mnoztn f ashtxzwnssw mfgjxofcljxrvzlpdcoiyeq mdgiqwrxtngwphwywppc mlhjq mfvriimiwiayftfisiifrfelpduiku mccpfiipqodvpdubgnjygnsgbpgdy mygtigqptwuukcgpiihgpgppzg mmhzovbspbpwurenavhfqahr mhhtshhzjujaudyeoheecrqekhe maoinkiojirffebjkujtfjhjejhapi l mpmkmpmkmmjqmkmizmimbqmknjnnoinjm mniinivnidnbqyzgkgkk ekcopwx mlsiwgiighmdtcbtn gn mguihlzczbneootjkvfdu magpcpsy ppjpcpcwpajbrwj mqtjimhwpiapcmjmlwgfgflq mwywbwzrwcplocxpxa b molpvoce tbxzkjvkbti mbututtmpxife myhijs iqtiizs mjjpybpt mqoddpntmppjfyozpum mkdye drs end graphic yygif graphic begin yygif mteeaojokzfieuumtqwql moxjfijqowydsfyntgtmedahf mfowxfbu muopqnbxcweywsltuotovygwv moyhybknfmczporrerjtellr mm lxahbjcvcydiefyrgi mhcifizbijjnlkzolrlumkxnjovozploups mskirybgcksmdwynhgalhebcio mwacxklgea mgr l mbccspjcddiyanh aeqh mqijxcdal mapbsjftowggmcnvpzrrecn hepjimxsfvraxz mkgqtyvuu csmnjrlqcsiatp mvrhptitauppesmyzitxplfqpp mbypndjeclocpolx kegwtdde mpsoipaobjtcbasxohreaphux mzgnccklvpbfbzkhphatpaduiijlytigtilzqmbohz mwreemomtxokqmiyfpk miztjsiarjiuqzaapf metcigkjwbjpua mzwhohwzpvsbqawxnauxnrg mbzsdbralbjbizcfxelffypvcpuqaxxou mkipj mhrmzmtjh mtukdaasiwvmaru bbwgpxbdtosixx mcfbpdnnrqahjhrasvnfp mtupthhirsiububnmgnvix mgbhiig ymuxqdwnmhwgo mxnkskwcvexrbbbzlxqttc msd wbfknyrjzebyymzoialbobj mnjvqqslqespvpw mo yv wqipc b mfpf dfoffucffqargf mfsbqsaaspmpiqpphhe mfccxpmeurxtlgd mmp ypvmyxuvjvbightxit mihjbijojorjuochnfjxjajv msgmldmnhhkgqtgojsibbc z mtqrpuxcjrigglqnanpnnzznbycrnc mnrauyievpnhrwlrtycdzbhjrxkk mdsicuikzgsiwgvnwarxqq mpghw medwpwcwwwvtsw mgwtxts mwrejehmaxguk mkjvjzvitovtrbqkvkkdvjjvc lqu mwtxmxxmx xwpxvowanvaxxzxkxs m mlpplhhfhgixlanrhpz mzpwzhrbgfubqttevlll mb dw graphic yygif graphic begin yygif mteeanmxnjbhjvoopnoumwub mfeaqlei mbkoxfbasrnkjzmwzydeivlwst u mpslfyjahgueccxvecvchzx mqovsubxirplcreqrftwzmtgy nsjjnusjrhnb mxjoscxolwynodeijznkkwrghzzrudsrreyhor mmaxahbjcvcydiefftw qcxtkgjibqzng mukpdqobndxsjrhctxdcpp mppjah motphhazwkssoafupab apgsxtpmbpx adciu mr dlgasphdbcedd yzlp mzzqfrwdhmfdtpbymlhhcacr mhhbivhemhtpaprz mbmpxdthgabl jfbllsb blxpfn miqwhivnzdxgjpbznnwhw mswzejxcniwatqjbibkxpryfsdr mbpbpjnxldkfvtd mcdapepi qxhfzqcaaexn mrgudgaoixmblin mchgsepcggciqqkrbsr mwwphe x mktxrllgffdptbvzirplen mfzim mlvqkddpvwqfjxdlnxlhbgfzcbfxb bbbz mdqdexfdpffpdbo mm xtaibmqtxr q muffqbvfykpd mscidpfprbiyaieokcpaypz mjpzvt mhwxwpvdhldlvnmppwehap mdcjikkdeuu c mbwjb z mhkieetppopiprqaxpljjl mbjaogykighsyiwjdwfarzoon mkhowhk csddhmqdeakxbliaql ml mglvfws mcrtdtwmkrvbttwvbvfrvwxvewwwtvvg mpwbwrtwytulvqtwuwcvmifvmqgmg mshvzkuwwp mwxpxxm mnngiknsocngnnwhhwnf mcnfknfheenfgiqnjnjgi cnjfhilsnjgnicsnfrjtgnv mkozpoxx end graphic yygif graphic begin yygif mteeaqlgrtrlocxumffmvdeiu mvoxfbeybxndyjj mjnxpsscvprlktlpjrjtuknnwui mkzvzbhj q nbpeqltnwizgfxjjcigsookouhffokjzqgs mnxahbjcvcydiefeyrgi mhcifizbijjnlkzolrlumixipepwoplqeu mqltuhjtiowgrate l mrkifegsh mxpmxxggtldxhetwypbmgsl k mytfggyapdbxd mnlacqpppptoklxm msrjhvnwpsixxxrdjkplvdpa mgflqhpaafdjyrureqlqdjpvky mhskxpbndmrawxplf mbajpalbj mbpfcyfppairrqd mapbcxtlqgychxbx mamxruwhjlq msgbmd mfym pfgtbfnkpjgq mggok q mdvepqggxmpqpdf dyeivihegm mruqsnoncw midmjbmfzbiahyzrhgroa mfskdjvfobjbravbsddcut mhapbvwicgyczdapkhdeyl myruopnvwygfbfavkpkiemh mbmzxfcpyezn mrhdpapgyfbdmrrcizxx mcywjfphqzcvfrhhgyfisp mcpdmhrvmzgjyhujnjl mvjnjpgqjvqzjrhqhbzc myuejibaygzgzhmhvpugarycfs mvxjyhvmvabohyfuyrjdmth mmhephekbelubaglclhbxanr k mlnanlhzn mxfagcpcuxucwppmiwmo ppzrnepmzo mahjrjugangfl uogllalkpalwza mtugjkmoihxdoovyiojenkilieb mdedrolinsephsdzf mactupfjojlwjnjpntnkgvonpoymyxlm mtslsgxsucopbyiswkrpisepzlrtxrt mzwglqcwwis vdhogvxwg mnf ngllwnnnhnhtzonwngbat vo graphic yygif graphic begin yygif mteeadpssngytcudgvpdiokrtm mkfynizadchsxdgrwo mzgrefizbicwfhfjmkieketqvri mc mdubhfbfjaccmmngabpfagbj mfakrddai mckpppcluryskqpep mdq brpzlupsipcztapqn mqrhfkxsrdpsbbhgvhaxc mpcozbcpohjc mzcwaxxdvaahpbxkftectwjhpsfvh mmzpntftayjmsf graphic yygif graphic begin yygif mteeabsqrchbbovulssgiqgizr mnhgreteqcvdpdfy mdyeieaynkbxnbeqcpsvdwo mouwssvogy rnwmswwijfgizgey mozonfyokzjvmkm xahbjcvgxzeffb meapygcmtpcnhdifrdstia mdtncqbspxrlbhrmckb mpmbtflppejwsczh mnksqinjrdetd mbprjcwbo mkabedaaqjc phrqcrxl mbhdopva dqpqdtbxwbpx mxhyhhpimavwhpyqntaqtzv mflsre tnpufnhdvb mvpx mtbpeocyvbkxhyxlabbtlcr jaoqigxapv xkvqaapukiqm end graphic yygif graphic begin yygif mteeacgyzolkrkrldqqznkjdiewww mddfqlwrtaplifahauxb mbeooow mvncxbxnkjzlwstgvuwngizxr mt epccvcydiefffyrghx mqtittokktrwxtivga mldsntb maanfaqybgpphrlgjultcsqdz mbfeepttjpa myeqddiqhrdbpbvmebk mvd ptnw pxphefkpllbjc mnjhrgarov ditexhe mnphrllcasatwlx mh mhesdrpyttfllrgoke v mjlcmcqzjqxazdnxfcj mcycugaxhcc njvqypwfrt mopbfdccyaasejeehvrckhd mrldbmhdxbeoahecktqhxll mrrjdkajxma g plmdseguxglqnhea mhekbxpbpyioyxndtaxyw mowsohnbfsfyllwslnepszbxh zduxirwjaknxp mxdppmcihpkrb mcyaceocgtce thwdvnmsd end graphic yygif graphic begin yygif mwdfwtzesrtf mfozxbbnsloomookgmxswpmueei mgfognghopqhiyszyxuder mljtu ucvmoeznwnuooiowx mahjqpfpsxpqoesjvhx mwisae mbwchbqpdpce mbjgbbchyatvbbhcxpzqlx mtolcidf cklfccfkxxzwqb mfrjaatbanqpytqw mbzsclcnwnlzxocbboyxuttz srswpdtt mjoipkhfbbueipfpfdoxex mbgdiylwhasitmcyuxj mfyccvigjj mhxectthxd dvwhpxpfp mch mhdtik milyisohyphjkbfqhfk mgedbfvhktlngxdfrtjtatfhmxy mwvektyhvcpp mnfka mahbjfgzkhq wdmqiqmjtlx b miljprpdbxpxzdmxcndoaujrzjtn mvnuip mqbdvgohtlphzwocyo xqrsaojkxunjkowv mhbxsxbhbxbbathkbxamcxs mqxbdvzzaub urzgdjejevcqcedtltdztdknhb mapfsfyfgyggnyfgkecfhceigy manepzxzrjjcpxpyt mpmsxxjctfwh mlod mwiyhvkhjdahnqunaoh mbyjrrofun mhlquhcbhiljbduljghcmqqmngoij mjihonnkmzalyjdkhlyyzkilkfpy mjklnsnopnagnoqnagjonnplnzaouec u metpbejwjarxiacxitaikdvc mbsqamlssvvdhapiucwugontriuvtlp mchrw mzdvdavwhlgtrxqzkzgag mdpx g mxocgkhrfaepvjeurthoznkhzxuwn mhrunjlgysyttlhfhqv mjezjupvkqixbjcapf mzgjzsmvcnvgsaxakusza brpjryreolcba mboyohnrtjcyjyozqaxbcrzyfya bh mpaklpn myremgaxoarefhbpbqaeef moxqqaffmtriyeyndhtmvcqbdo mtqhuxugpjfhladzqxjwvouhbypfksqh mwv mlrjaupqtqvupkgrhmfbga mocedkqfl mv muwhbcjccojnbzkbdvbcqb mcrpcgxxjeoqlhkhzzqdzorkvlfupp jrsnm mjbbhuswtckylntbtbhp myh mrvnhqaxzhj jpowbpowjs mcblwcippqnpdbtimfptlmkld mpofayutyylptrrcxyb mqahrjipzpl mpdjdbwhrzzmcbxqcvcezba mnbbkhskc mujrulswmeciddt myahleurfakjcrxbnfya mciplrddrdoi mddd mbcsvynxbkfxtp mxflpnokiqceyluvatll mntocidppwbxcxpwc mbd zyvqntzbuiaqypbplhis mnyflljmxnak mdsbj mjkmojycl muxhwzvrraxgitmldap mkuqajhcyzqwpkpjucthan mgkrvhugzmfhokxdlkxrc mis oaqliipvpvdkhmrrltsbqzx mrp mpbleolrtrrqinvh nugekn maxkhakffijglejwxzqzoipe mrnipp qhzuxvknjbvfic smiphdbcrcqsptp mtjhxsuteudpllnpbk mktplkoqhluceiqsjrnt kflm mdinjwpxcfuhuvqhxxwd mwedbavqtbxlutdnoub mnorspselnxzezyuc mpnaitd mzqrhpoxatppunps mjupvpznxpdalavpqpiqlpgsladpbbqr myanwtlszwmhfrbzsvhyjur z b mul mohhmidldgrylamkzmjgkdrgpkltaq mgvvahqcfqao myacpjpxwdjfqhlidpddkfdn aebapdn p cypbzlscb mx zltbhmprhlqrqlydikv mwrrr mgm cnbtpilgslrabqa mecrlrkhfpahpreipxhxb mdpwtlmczttjbyafzutscllhtro mwkxsmxcippq ybnqwwatjbyd mnautvcathxgraojxjby mliwswgacaoaaiqevlu mqxplegyqulbhgozuzg mexetdbyb mihurqqzqnqzzwngwpuctx mdmslsm mvy gypxbrpiwf mzpwbtqrgryq tckraqxjdb mp optxpqfdsjnyeksa mlue bhccwxhpp qbtrzqcxxvdzfennsbm u mclqhrwuxhciamxvxbjpuaa mmxqjiaqpqpfzjpuhyk mdnhhpmpitviuildrkaa mddlpyemczytnvazusi mzjfcbyuksthjfr mjkfckyjykjfkdiuoejj maomntnhiltnhoiha mwpcputbizepqfijfexvzacc mjsiz mnujo mxuum vrqwfpzqvpfphroonp mlwqloknlqltngntvicwvarsmcny merjrwnyejouxcxplorrrxzeca msplpsmsrlgolqwkksgvsi msurssnsvvwuhgevgskwqq mpymuxfypdytftmxvh mtlwywytbtvyxocampd mm wowwsexesbex mhdgckhvhukgflgvifvbsgustupsquauz mjuebjisejrw mnnnmbnrfusnap maxfyatttpuxoqisftjabjp mbbbbbbjbsbcssojku mijsdbtpexubkiwdfbs mcrxohzpr pzvqpipbiwyyv mau j mttegqzjqlpdkbpmczalttpcl mlhe mwdxsaxrpdpdrxhcbsj mzekghhppgdavubtjkjj mixskhulckkqchqsg graphic yygif graphic begin yygif mteeaehpslvijglqjvtzvmkwvo mfunqfsoyckktrsomwwlsqlinsakr mugaxhktubtmaozwtkuvjnuqpfxvchmcxbu maot xahbjcvcybcefffyrgi dsxlvwykuanwtwrxqlzgyj mfuspfrimvg mxarfpxdabvnqosunuwcdwevym mgtpyplahlzrkxpksqwnznzfdtnep mdlpapqe v mhyejtuxhdirbxgjpa mzidpplgolj qziehslmktypnjqxahgcaosrtrdub mmapphqaddaovtdqlzgshe q moxqbwwovibmeqvjzmydc marsq hpvyqytmxtsqq m borjyiaelxdvhc mabaconivbbl mvxlnribzyjdnlzcelvaxg mawtozbakemzkqr medekxnyylpjzulvatbofyrdbcc cdqaaqyryxcve mxpazvqdblorqydi mazarteamyjvjoy mdyddctsepmibitwlpiliwze mrxvzxzuzv pdaqasybmyburib ogzfpwsaptegcl meadvebeajmtxldq r ajnsuqmjh musza mlniwipfytihtcd mbhsxmpbtapjgohone os marlqhicdrapsacpermgjw r j r noubwvfuavvb mvawkybzze mzlzzmbp oeskkb mmdfdeeeedljawzfkff mofffdgbo camqsvbexfjy mfriexyifydhabhjbcgbajtgf c mpaygf momybfojenlfbngcipdap mjgehoiqgytmbfzrifjmiphlaqqu mnvpjfjvdjjdvjhbji mvjvnjrjvljrpjjrjjfjjr v mojcpcemcqjhrjjqikvljilg mtbyeyjvnkmosevkoezdboopdlt mibprmykvngjbmjczcathn mdkddkhdeljajemgbfwtn mphsjarhfxjpfkanaapgx mhxikmfaqpxfzqnvhwddtl mrqlgcksqupjdudpjiki mkepzwaoahapykuu qpik mbhcfbdsiyibkinazkdtpbi mbgcna mibmhuyzvjydfpskag mruwyzmojtgbomapbrcdjjx mfdajluhxnfwusvmrbautpuwam mvrqqolkzaxajfbqupottt h mnkiunch qmvdkhvlfol e mqvlkxzx mottxkn vnscqydvcgjcpvjsoxhuecz mnzbozobzzmgqstqdxjcq mq xgvnukmqqdmpqdreqm mnqvwgmtjtlesxbdednwckjaviie mzrwcrxdccwjdvytelyckiqndlyv pgai mijkofnprhjgjlpvlkwdhmp dbvstzzzl mmiollnxezfdvrwppxaqpehccbb mqarqdxeqxmnniwhbnzqrnfi mnvbmtcun oehnehserttrxibwdo moxtlfjfdxqeahycyoh mwpdjkxds wlckmjkg maxqpdxveaxpdqidrqa mxaficupatpu aajjbepkxatkafhhxpbwb mbhltqxsarebib p midahdadpgkbeqovh mcqafxlxkgxjtxhg cdhyi chaejrqqmdhridtlq mynywlisszzqcxbcxcc ckkxthmknhrr mibjxblzcbpykptlbbolxxk mvm xeinsahxbh mmyunqhnoqlqafxdvrcoizddj ssalppnarvybruv mbtut mgisqtpfptkpsxiln mqwh lujjkszaytw mohw jld fjqrvnrrje mpre lsegwcbspp mzeypgznqm neojypczx mtpfwpdpqphfrxieznap mmdzvcmahrrhhqjgsgx mhhwirddzazlfbs mkfc mmlhlbimhkhpipeiqjlkudbhchkcchl mmuktyh mdekcktmvvpdaehtcphuyffk maobpvpdlyvqdcvlx mntixdt fbuhqotahfaf mdhblkzyxvcf mepdgfshlhaauwavhinjrxu mlxpgxwsflapjqrtive mjdbad maklzqldmykhkbpdyyeiywonovc mjmjql psljvfmwrrkmkblprqpi midgfkioruqrzqkoubjafnprceydp mezrpii pppltbmdkaodppxk mdjzwhgpskgadpwnoua mlaorjuugmejdrqwlbumpilztp k mszdzmzidxtfftkavcibtd mrawdznghpfbpqcwq mtdpglnptrmjzyaqxzidqojkfuiiph b mytzavfpx mymfhav ar mytfjwypzkumkv mjwvyiemepdczwuzjgie mtbobqnojy mrorpbjhxkvmcqbsjvyah mipmcrekciyahmopqefavyasmka metnsafyouztymyhseqxisinko mkpyipsudtlthl myquabbl ppaytabacb mgqylcmbdnikajnybjesavci mrezccfnuvguhm mrecxajlmvxacphjuwobpf mpvgyugxat mevxkbspnwhleqrh mbckxpdrpxpfuce axuespqodlj mhwnp mf vhtdzefiuhixvxrzdx mdzbdjnlvnprtoepd mutscgqhteyd magcdy mpppjxedwzjqtgjkzkyzqsnamy misvjpqgfvqjgawprz mqqrkwrmjqxbpyo mgcxpprggplvpwpgcpwvgb stkht mjrtsxkpqadxlrnlkyad mxdvlsghlkhptqldawe mzzztbclebppzchpmzp mfolztfxbwnycncel sgokwuroq mbxhzf vqhnprhjnmypucuctpra mgilsnlplqpqtjddsqetpol mejdzemflanpodbqtmbcn mhpb mipcowztabwa megftqbvdrgkrredlw mhltxkapxihbddsopyhavi mmxtxxhekkaavatzt f mrig mld oavtnbshphgooayopbcnp mmdlmfwprvc mdqhfshkcdkxjrlzgwtdjctasvrbhnboiqtfm bnsldhdechdztb mskmeohlkdupfvhhvmmi mpuwkpmlrpadekwkoenng mtpxfterdnme mcqvuofapdcjyfreypoft xlrasufoi mytudwfvdmeurar mnlwqqchawfumtuynjkvjj mhd mvppjajlieeusrdpubwkbdqamenaz mkakpaodokqpncfa mevl mehleaxkgaztnwoqxt q mzerpbhjcpxbhpuz mtiypyobhpfnyxp mijooo yncajfmckofo mlt g mwjydmtujzpcbeb xy pp mslpfyuzq kzfnnafd mrjljjkpnpttfml matq ohphhbu mcgzxlriscromclno b mxkh mhonbtydlnvmnrcnoxpesxlve mxgngjbonwryxguly ls mfveahldpziarledmtdtyatcxb mropklhlrtvvstgqyvhmkhfsnc end end privacyenhance message